



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|---|--|
| (51) International Patent Classification ⁶ : C12P 17/02, C12N 3/00, 1/00, 15/01, 1/20, C12P 7/62, 7/26 // (C12P 17/02, C12R 1:07) (C12P 17/02, C12R 1:125) | A1 | (11) International Publication Number: WO 99/32651 (43) International Publication Date: 1 July 1999 (01.07.99) |
| (21) International Application Number: PCT/CA98/01150 (22) International Filing Date: 18 December 1998 (18.12.98) (30) Priority Data: 08/995,960 22 December 1997 (22.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/995,960 (CIP) Filed on 22 December 1997 (22.12.97) (71) Applicant (for all designated States except US): BCM DEVELOPEMENT INC. [CA/CA]; Suite 218, 125 rue Dalhousie, Québec, Québec G1K 4C5 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): PAGE, Michel [CA/CA]; Suite 218, 125 rue Dalhousie, Québec, Québec G1K 4C5 (CA). LANDRY, Nathalie [CA/CA]; 1060 de la Voie Ouest, St-Jean-Chrysostome, Québec G6Z 1K1 (CA). BOISSINOT, Maurice [CA/CA]; 109 Jean Bruchési, Saint-Augustin, Québec G3A 2N2 (CA). HELIE, Marie-Claude [CA/CA]; 453 Place St-Laurent, | Cap-Rouge, Québec G1Y 3G9 (CA). HARVEY, Mario [CA/CA]; 1067-F De la Prairie, St-Jean-Chrysostome, Québec G6Z 2G3 (CA). GAGNE, Martin [CA/CA]; 6400 Pise, Charlesbourg, Québec G1H 7A7 (CA). (74) Agents: COTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |
| (54) Title: BACTERIAL MASS PRODUCTION OF TAXANES AND PACLITAXEL | | |
| (57) Abstract | | |
| <p>The present invention relates to a method of obtaining different biologically pure cultures of bacteria isolated from different species of <i>Taxus</i> such as <i>Taxus canadensis</i>, <i>T. brevifolia</i>, <i>T. baccata</i>, <i>T. cuspidata</i>, and <i>T. hunnewelliana</i>, wherein the bacteria produce <i>in vitro</i> taxanes and paclitaxel, and wherein the bacteria are of the genus <i>Sphingomonas</i>, <i>Bacillus</i>, <i>Pantoea</i> or <i>Curtobacterium</i>. Also, the present invention relates to a method of a bacterial mass production of at least one taxane or paclitaxel. There is also disclosed a novel bacterial taxane. The present invention also relates to the use of different biologically pure cultures of bacteria isolated from different species of <i>Taxus</i>, wherein the bacteria are able to biotransform pro-taxanes. There is also provided a process for improving taxanes and paclitaxel production of taxanes and paclitaxel producing bacteria which include culturing bacteria in the presence of a mutagenic agent for a period a time sufficient to allow mutagenesis. There is disclosed two new mutated bacterial which have an increased yield of pro-taxane biotransformation.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

BACTERIAL MASS PRODUCTION OF TAXANES AND PACLITAXEL

BACKGROUND OF THE INVENTION

(a) Field of the invention

5 The present invention relates to the production of paclitaxel and derivatives thereof (such as related taxanes) using a plurality of different bacteria isolated from different species of *Taxus*, and also to a novel taxane. There are disclosed methods for the iso-
10 lation of these bacteria and the screening tests that were used to provide evidence that paclitaxel and taxanes were produced by said bacteria. There are also disclosed methods for the biotransformation of pro-taxanes by said bacteria.

15 (b) Description of prior art

 Paclitaxel, also referred to as Taxol™, has been first identified in 1971 by Wani and collaborators (Wani MC et al., 1971 *J. Am. Chem. Soc.*, **93**: 2325-2327) following a screening program of plant extracts of the
20 National Cancer Institute. This complex diterpene showed cytotoxic activity against several types of tumors and is presently used in the treatment of some cancers such as ovarian and breast cancers. Clinical studies suggest that Taxol™ could eventually be used in
25 the treatment of over 70% of human cancers.

 Paclitaxel differs from other cytotoxic drugs by its unique mechanism of action. It interferes with cell division by manipulating the molecular regulation of the cell cycle. Paclitaxel binds to tubulin, the
30 major structural component of microtubules that are present in all eukaryotic cells. Unlike other antimetabolic agents such as vinca alkaloids and colchicine,

which inhibit the polymerization of tubulin, paclitaxel promotes this assembly of tubulin and stabilizes the resulting microtubules. This event leads to the interruption of cell division, and ultimately to cell death.

5 The major obstacle in the use of paclitaxel as an anticancer treatment is its supply. It was originally isolated from the bark and leaves of yew trees such as *Taxus brevifolia*, *T. baccata*, *T. cuspidata* or, *T. canadensis*. The low yield of the isolation of
10 paclitaxel (0,016 g%) and the limited availability of the trees have forced the scientific and industrial community to find alternative ways of producing paclitaxel.

 The antitumor property of taxoid compounds has
15 also lead to the generation of new anticancer drugs derived from taxanes. Taxotere™ (sold by Rhône-Poulenc Rorer), which is produced from 10-deacetylbaccatin III by hemisynthesis, is currently used in the treatment of ovarian and breast cancers. Furthermore, Abbott Laboratories
20 is conducting clinical trials with a drug derived from 9-dihydro-13-acetyl baccatin III, a natural precursor specific to *Taxus canadensis*. The increasing demand for taxanes highlights the urgent need for renewable and economical processes that would
25 not endanger plant species.

 Presently, industrials are producing paclitaxel through hemisynthesis from baccatin III, a natural precursor of paclitaxel. However, this process still
30 relies on a plant substance that must be extracted from yew trees. The first complete chemical synthesis of paclitaxel has been achieved in 1994 by Nicolaou et al. (1994, *Nature*, 367:630-634). This is a multistep proc-

ess and the overall yield has made this approach non economically feasible.

Plant cell culture of *Taxus* species is another approach explored by many groups (Yukimune et al., 1996, *Nature Biotechnology*, 14:1129-1132; Srinivasan et al., 1995, *Biotechnology and Bioengineering*, 47:666-676). Somehow, this process is limited by the amount of paclitaxel that can be produced, the length of incubation time required to obtain significant yields, and the application of plant cell culture to the large volumes required by the industry.

In United States Patent No. 5,322,779, in the names of Gary A. Strobel et al. disclosed a fungus isolated from the bark of a sample of *Taxus brevifolia* which is able to synthesize paclitaxel at a level of 24-50 ng/l after a period of incubation of 3 weeks. Later, Strobel et al. (1996, *Microbiology*, 142:435-440) reported another fungus, *Pestalotiopsis microspora*, isolated from the inner bark of *Taxus wallachiana* that can produced up to 55 µg/l of paclitaxel within 5 weeks. Somehow, the long periods of incubation and the large volumes required to extract significant amounts of paclitaxel reduce the profitability of the process.

In United States Patent number 5,561,055 (issued on October 1, 1996 in the names of Michel Pagé et al., the Applicant), there is disclosed one bacterium, which was referred to as *Erwinia taxi*, for the production of paclitaxel. Since then, this bacteria has been characterized as *Sphingomonas taxi*. This bacterium was isolated from *Taxus canadensis*. It would be highly desirable to be provided with other bacteria having

highly diverse metabolic capacities isolated from different species of *Taxus* for the production of paclitaxel and related taxanes at higher yields.

It would also be highly desirable to be provided
5 with widely different bacteria for the mass production of various different bacterial taxanes.

As mentioned in International Patent Application published under number WO97/16200, biotransformation process may be used for the generation of new taxanes
10 molecules that lead to new therapeutic drugs. It would also be highly desirable to be provided with new strains of microorganisms able to biotransform taxanes compounds for use as therapeutic agents or to be modified by hemisynthesis.

15 Genetic manipulations of bacteria can increase the activity or the production of certain proteins. It would also be highly desirable to be provided with mutant of our original isolates that could produce and biotransform taxanes at higher levels.

20

SUMMARY OF THE INVENTION

One aim of the present invention is to provide a plurality of bacteria for the mass production of taxanes and paclitaxel.

25 Another aim of the present invention is to provide a method for bacterial mass production of taxanes and paclitaxel which overcomes all the drawbacks of the prior art.

Another aim of the present invention is to provide
30 a novel process for the production of taxanes and paclitaxel. The industrial application of this process would provide alternative renewable sources of taxoids

compounds for the pharmaceutical industry.

Another aim of the present invention is to provide a biotransformation process in which plant-derived taxanes are converted into substances that may be useful for the production of other therapeutic compounds.

In accordance with the present invention there is provided a method to obtain biologically pure cultures of bacteria isolated from *Taxus*, wherein said bacteria produce *de novo* taxanes and paclitaxel at a concentration of about 1 to 25 µg/L, wherein said bacteria are isolated from the inner surfaces of different species of *Taxus* including without limitations *Taxus canadensis*, *T. brevifolia*, *T. hunnewelliana*, *T. baccata*, and *T. cuspidata*.

In addition, said bacteria are capable of producing biotransformed taxanes wherein pro-taxanes are added to their culture medium.

Such biologically pure cultures of bacteria of the present invention include, without limitation, bacteria of the genus selected from the group consisting of *Sphingomonas*, *Bacillus*, *Pantoea*, and *Curtobacterium*.

In accordance with the present invention, the bacteria include, without limitation, *Bacillus cereus* ssp. *taxi*, *Bacillus megaterium* ssp. *taxi*, *Pantoea* sp. BCM 1, *Pantoea* sp. BCM 2, *Pantoea* sp. BCM 3, *Bacillus cereus* ssp. BCM 4, *Bacillus subtilis* ssp. *taxi*, *Bacillus megaterium* ssp. BCM 9 or *Curtobacterium* sp. BCM 5.

In accordance with the present invention there is also provided a method of bacterial mass production of taxanes and paclitaxel thereof which comprises the steps of:

a) culturing the bacteria of the present invention in a growth-supporting nutrient medium capable of promoting growth and reproduction of said bacteria, and wherein said culturing is effected for a time sufficient to allow production of taxanes and paclitaxel; and

b) isolating said produced taxanes and paclitaxel from said bacteria or culturing medium of step a).

In accordance with the present invention there is also provided a process for improving taxanes and paclitaxel production of taxanes and paclitaxel producing bacteria comprising the steps of:

a) culturing bacteria in the presence of a mutagenic agent for a period of time sufficient to allow mutagenesis;

b) selecting said mutants by a change of the phenotype which results in an increased production of taxanes and paclitaxel.

The mutagenic agent may be a chemical agent, such as daunorubicin and nitrosoguanidine.

The mutagenic agent may be a physical agent, such as gamma radiation or ultraviolet.

The mutagenic agent may be a biological agent, such as a transposon.

In accordance with the present invention, the mutated bacteria include, without limitation, *Sphingomonas taxi* D200 or *Sphingomonas taxi* D201.

In accordance with the present invention there is also provided a method of bacterial biotransformation of taxanes and paclitaxel thereof which comprises the steps of:

5 a) incubating the bacteria of the present invention in a growth-supporting nutrient medium capable of promoting growth and reproduction of said bacteria, and wherein said incubation is effected in the presence of pro-taxanes for a time sufficient to allow production of taxanes and paclitaxel; and

b) isolating said produced taxanes and paclitaxel thereof from said culturing medium of step a).

10 In accordance with the present invention, there is also provided a process for improving biotransformation of pro-taxanes into taxanes and paclitaxel by taxanes and paclitaxel-producing bacteria comprising the steps of:

15 a) culturing bacteria in the presence of a mutagenic agent for a time sufficient to allow mutagenesis; and

20 b) selecting said mutants by a change of the phenotype which results in an increased biotransformation of pro-taxanes into taxanes and paclitaxel.

In accordance with the present invention there is also provided a method of bacterial biotransformation of pro-taxanes into taxanes and paclitaxel thereof which comprises the steps of:

25 a) incubating the mutated bacteria of the present invention in a nutrient medium, and wherein said incubation is effected in the presence of pro-taxanes for a time sufficient to allow production of taxanes and paclitaxel; and

30 b) isolating said produced taxanes and paclitaxel thereof from said culturing medium of step a).


In accordance with the present invention there is also provided a novel bacterial taxane having a characteristic ultraviolet spectrum in HPLC as shown in Fig. 9B, Electrospray Ionization (EI) spectrum as shown in Fig. 10A, and characteristic fragments as shown in Fig. 10B.

This novel bacteria-derived taxane of the present invention is produced by at least two species of *Bacillus* (*B. cereus* ssp. *taxi* and *B. megaterium* ssp. *taxi*).

For the purpose of the present invention the following terms are defined below.

The term "taxanes and paclitaxel" is intended to mean any paclitaxel derivatives or precursor which have retained or not the taxol-associated cytotoxic biological activity or are thought to be precursors in the synthesis of paclitaxel. Such taxanes and paclitaxel may be selected from the group consisting of all the diterpenes isolated from any *Taxus* species. The production of all taxanes by bacteria, whether pharmacologically active or inactive, is contemplated within the scope of the present invention. Taxanes that are produced by the bacteria of the present invention may be as such found in *Taxus* plant species or may differ from the ones found in *Taxus* plant species.

Exemplary taxanes which may be produced by the bacteria of the present invention include but are not limited to those of the following Formula I:



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} ,
5 R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1 below.

However, since bacteria have highly diverse metabolic capacities the taxanes and paclitaxel must only correspond to Formula I, whatever is the nature of R_1 to R_{17} substituents.

10 The term "pro-taxanes" used in accordance with the present invention is intended to mean any precursors of any taxanes in the biosynthesis pathway of paclitaxel in plant, fungi and bacteria, including, without limitation, 10-deacetylbaccatin III, baccatin
15 III, cephalomannine, taxinines, taxuspines, taxusin, 7-xylosyl taxol, 7-epi-10-deacetyl taxol, 10-deacetyl taxol, paclitaxel, 7-epitaxol, taxadiene, geranyl-geranyl-pyrophosphate (GGPP) and farnesyl-pyrophosphate.

20 Exemplary pro-taxanes which may be biotransformed by the bacteria of the present invention include but are not limited to those of the preceding formula I where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1 below.

25 Exemplary biotransformed taxanes of the present invention include, but are not limited to, those of the


following Formula I where R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1.

Table 1


| Compound | R ₁ ⁽¹⁾ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ ⁽³⁾ | R ₇ ⁽²⁾ | R ₈ R ₁₇ | R ₉ R ₁₀ ⁽⁴⁾ | R ₁₁ | R ₁₂ ⁽⁶⁾ | R ₁₃ | R ₁₄ | R ₁₅ ⁽⁵⁾ | R ₁₆ |
|-----------------------------------|-------------------------------|-------------------|----------------|----------------|----------------|-------------------------------|-------------------------------|--------------------------------|---|----------------------------------|--------------------------------|-----------------|-----------------|--------------------------------|-------------------|
| 1) pacitaxel | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 2) 10-deacetyl- cephalomannine | ceph | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 3) 7-epitaxol | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 4) 10-deacetyl-7- epitaxol | tax | CH ₃ | H | β-OH | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 5) 7-epi- cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 6) baccatin III | α-OH | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 7) 10-deacetyl baccatin III | α-OH | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 8) cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 9) 10-deacetyl taxol | tax | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 10) 7-xylosyl taxol | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-xylosyl | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 11) 7-xylosyl- cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-xylosyl | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 12) taxagifine | =O | α-CH ₃ | β-OH | β-acetyloxy | α-acetyloxy | β-CH ₃ | β-acetyloxy | H | α-cinnamoyloxy | methylene (=CH ₂) | α-acetyloxy | β-H | H | cyclo | α-CH ₃ |
| 13) 8-benzoyloxy- taxagifine | =O | α-CH ₃ | β-OH | β-acetyloxy | α-acetyloxy | β-benzoyl- oxymethyl | β-acetyloxy | H | α-cinnamoyloxy | methylene (=CH ₂) | α-acetyloxy | β-H | H | cyclo | α-CH ₃ |
| 14) 9-acetyloxy- taxusin | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-acetyloxy | β-CH ₃ | H | H | α-acetyloxy | methylene (=CH ₂) | H | H | H | CH ₃ | CH ₃ |
| 15) 9-hydroxy-taxusin | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-OH | β-CH ₃ | H | H | α-acetyloxy | methylene (=CH ₂) | H | H | H | CH ₃ | CH ₃ |
| 16) taxane Ia | tax | CH ₃ | H | =O | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 17) taxane Ib | taxsub | CH ₃ | H | =O | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 18) taxane Ic | taxsub | CH ₃ | H | =O | =O | β-CH ₃ | α-acetyloxy | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 19) taxane Id | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-acetyloxy | β-CH ₃ | β-acetyloxy | H | α-OH | epoxide | α-acetyloxy | β-OH | H | CH ₃ | CH ₃ |
| 20) 7-epibaccatin III | α-OH | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |

Footnotes

(1) "ceph" denotes




"tax" denotes




5


"taxsub" denotes



(2) "xylosyl" denotes



10 (3) "α" denotes the stereoposition of a stereomoiety below the plane of the taxane ring structure shown above



"β" denotes the stereoposition of a moiety above the plane of the taxane ring structure shown above


15



(4) "oxetane" denotes the moiety



20 which is




5) "cyclo" denotes the cyclic group formed by bonding the group



to the taxane

A ring as follows:



6) "epoxide" denotes the moiety



5

which is



The term "taxol-associated cytotoxic biological activity" is intended to mean a cytotoxic activity which is sufficient to promote the assembly of tubulin and stabilizes the resulting microtubules of cancer cells causing the division of the cells in two equal daughter cells to be interrupted; and sufficient to cause a disruption in the dynamic equilibrium which exists between microtubules and their depolymerized tubulin dimers, thus preventing completion of the mitotic step which causes a lethal metaphase arrest of cancer cells.

The expression "cancer cells" is intended to mean any cancer cells which include without limitation, ovarian, breast, lung, head and neck cancer cells.

The term "growth supporting nutrient medium" is intended to mean any culture media which include, without limitation, carbon sources, nitrogen sources, amino acids, vitamins and minerals.

The term "intercalating agent" is intended to mean any molecule binding to the double stranded DNA structure which include, without limitation, daunorubicine, ethidium bromide, acridine orange, acriflavine
5 and epirubicine.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1A shows the elution profile, according to HPLC method no. 1, of an organic supernatant extract of
10 a bacteria in accordance with one embodiment of the present invention, referred to as *Sphingomonas taxi*;

Fig. 1B illustrates the UV spectra of paclitaxel obtained from a standard and of an organic extract of supernatant of a bacteria in accordance with one
15 embodiment of the present invention, referred to as *Sphingomonas taxi*;

Fig. 2A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention,
20 tion, referred to as *Bacillus cereus* ssp. *taxi* using HPLC method no. 2;

Fig. 2B illustrates the ultraviolet spectrum of paclitaxel produced by *Bacillus cereus* ssp. *taxi* compared to a paclitaxel standard;

25 Fig. 2C illustrates the ultraviolet spectrum of 7-xylosyl-10-deacetyltaxol produced by *Bacillus cereus* ssp. *taxi* compared to an authentic standard co-eluting with taxinine M;

Fig. 3A illustrates a typical chromatogram of an
30 organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Pantoea* sp. BCM 1 using HPLC

method no. 2;

Fig. 3B illustrates the ultraviolet spectrum of 7-epi-10-deacetyltaxol produced by *Pantoea* sp. BCM 1 compared to an authentic standard;

5 Fig. 4A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus megaterium* ssp. *taxi* using HPLC method no. 2;

10 Fig. 4B illustrates the ultraviolet spectrum of the bacterial paclitaxel produced by *Bacillus megaterium* ssp. *taxi* compared to an authentic standard;

Fig. 5A illustrates a typical chromatogram of an organic extract of the supernatant of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus cereus* ssp. BCM 4 using HPLC method no. 2;

20 Fig 5B shows a substance having the characteristic ultraviolet spectrum of a taxane compared to a standard of 7-xylosyl-10-deacetyltaxol co-eluting with taxinine M;

Fig. 6 illustrates the cytotoxicity of organic extracts of microorganisms isolated from different species of *Taxus* on CRL-1572 cell line as well as the cytotoxicity of taxanes and paclitaxel negative bacteria (STJ.BRP.K1 and *E. coli* TG1);

Fig. 7A illustrates the mass spectrometry of the substances eluted between 45 and 48 minutes using HPLC method no. 1 from an extract of *Sphingomonas taxi*;

30 Fig. 7B illustrates the mass spectrometry of a paclitaxel standard;

Fig. 8A illustrates the almost complete 16S rRNA

gene sequence of *Sphingomonas taxi* (SEQ ID NO:1);

Fig. 8B illustrates the almost complete 16S rRNA gene sequence of *Bacillus cereus* ssp. *taxi* (SEQ ID NO:2);

5 Fig. 8C illustrates the partial 16S rRNA gene sequence of *Bacillus megaterium* ssp. *taxi* (SEQ ID NO:3);

Fig. 8D illustrates the partial 16S rRNA gene sequence of *Pantoea* sp. BCM 1 (SEQ ID NO:4);

10 Fig. 8E illustrates the partial 16S rRNA gene sequence of *Bacillus cereus* ssp. BCM 4 (SEQ ID NO:5);

Fig. 8F illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus subtilis* ssp. *taxi* (SEQ ID NO:6);

Fig. 8G illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Pantoea* sp. BCM 2 (SEQ ID NO:7);

20 Fig. 8H illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Pantoea* sp. BCM 3 (SEQ ID NO:8);

Fig. 8I illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Bacillus megaterium* ssp. BCM 9 (SEQ ID NO:9);

25 Fig. 8J illustrates the partial 16S rRNA gene sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Curtobacterium* sp. BCM 5 (SEQ ID NO:10);

30 Fig. 8K illustrates the partial 16S rRNA gene

sequence of a bacteria in accordance with one embodiment of the present invention, referred to as *Sphingomonas* sp. BCM 7 (SEQ ID NO:11);

Fig. 9A illustrates a typical chromatogram of an organic extract from the supernatant of *Bacillus cereus* ssp. *taxi* producing a specific bacterial taxane using HPLC method no. 2;

Fig. 9B illustrates the ultraviolet spectrum of the characteristic taxane produced by *Bacillus cereus* ssp. *taxi*;

Fig. 10A illustrates the GC/MS (EI) spectrum of the purified specific bacterial taxane produced by *Bacillus cereus* ssp. *taxi* in accordance with the present invention;

Fig. 10B illustrates the mass-to-charge ratios of ions present in the EI mass spectra of the bacterial taxane produced by *Bacillus cereus* ssp. *taxi*;

Fig. 11A shows the evolution in time of two taxanes in the sterile culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* incubated at 150 rpm at 30°C;

Fig. 11B shows the evolution of two taxanes transformed by *Sphingomonas taxi* when cultured in the culture medium S-7 supplemented with 1% of an aqueous extract of *Taxus canadensis*, shaken at 150 rpm at 30°C;

Fig. 12 shows the HPLC chromatograms of *S. taxi* cultured in the S-7 culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* where sample name 8A represents the organic extract of the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, sample name S 24 hres represents the organic extract of *Sphingomonas taxi* incu-

bated 24 hours in the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, sample name S 48 hres represents the organic extract of *Sphingomonas taxi* incubated 48 hours in the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, and sample name S 72 hres represents the organic extract of *Sphingomonas taxi* incubated 72 hours in the culture medium supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*;

Fig. 13 compares HPLC chromatograms of the supernatant extracts of *S. taxi* (sample name: S 48 hres), *S. taxi* D200 (sample name: SC 48 hres) and *S. Taxi* D201 (sample name: SCP 48 hres) cultured 48 hours in the medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*, and the organic extract of the medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* (sample name 8A); and

Figs. 14A-14C show the characteristic ultraviolet spectrum of the new biotransformed pro-taxanes.

DETAILED DESCRIPTION OF THE INVENTION

Plants are hosts of a variety of microorganisms. The relation between the plant and the microorganism can be saprophytic, parasitic, endophytic or symbiotic. Whatever the relation, there may be genetic exchange between the species. *Taxus*, such as *Taxus canadensis*, which grows in some regions of the province of Quebec, shows significant amounts of paclitaxel in its needles and stems. Samples of *Taxus canadensis* from seven (7) regions of the province of Quebec were chosen as well as samples of different species of *Taxus* such as *Taxus*

brevifolia, *T. cuspidata*, *T. baccata*, *T. hunnewelliana*. Several different bacteria of different genus, such as *Sphingomonas*, *Bacillus*, *Pantoea*, and *Curtobacterium* were isolated from inner parts of samples from
5 different species of *Taxus*, and all demonstrated taxanes and/or paclitaxel-producing properties.

Bacteria described above, produced taxanes and paclitaxel in fermentation procedures. Bacteria are cultured in a appropriate growth supporting nutrient
10 medium containing ingredients known to those skilled in the art for the cultivation of microorganisms. Specific examples of appropriate such media are given below. Temperature of cultivation ranges from 10°C to 35°C, and aerobic cultivation is generally preferred.

15 Taxanes and paclitaxel are generally excreted in the supernatant, up to 10% of those substances remain in the cell. Taxanes and paclitaxel thereof may be extracted by performing an organic extraction with an appropriate solvents such as methylene chloride or
20 ethyl acetate.

In accordance with the present invention, various bacteria producing taxanes and paclitaxel were isolated from different species of *Taxus*.

One bacterium isolated from *Taxus canadensis*
25 allows for the production of taxanes and paclitaxel at a yield of 1 µg/L, referred to as *Sphingomonas taxi*, has been already deposited at the American Type Culture Collection but was identified as *Erwinia taxi* (ATCC, 12301 Parklawn Drive, Rockville, MD 20852 USA) on April
30 25, 1995 under deposit number ATCC 55669. The deposit is also available as required by Foreign Patent laws in

countries wherein counterpart applications are filed.

The other strains of the present invention have been deposited at the American Type Culture Collection (ATCC, 12301 Parklawn Drive, Rockville, MD 20852 USA) on December 18, 1997 under deposit accession numbers as set forth below. The deposit are also available as required by Foreign Patent laws in countries wherein counterpart applications are filed.

| Strain | ATCC No. |
|---|----------|
| <i>Bacillus cereus</i> ssp. <i>taxi</i> | 202061 |
| <i>Bacillus megaterium</i> ssp. <i>taxi</i> | 202062 |
| <i>Curtobacterium</i> sp. <i>BCM5</i> | 202063 |
| <i>Pantoea</i> sp. <i>BCM2</i> | 202064 |
| <i>Bacillus megaterium</i> <i>BCM9</i> | 202065 |
| <i>Bacillus cereus</i> <i>BCM4</i> | 202066 |
| <i>Sphingomonas</i> <i>taxi</i> <i>D201</i> | 202067 |
| <i>Sphingomonas</i> <i>taxi</i> <i>D200</i> | 202068 |
| <i>Sphingomonas</i> sp. <i>BCM7</i> | 202069 |
| <i>Pantoea</i> sp. <i>BCM3</i> | 202070 |
| <i>Pantoea</i> sp. <i>BCM1</i> | 202071 |
| <i>Bacillus subtilis</i> ssp. <i>taxi</i> | 202072 |

10

In accordance with one embodiment of the present invention, the bacteria isolated from different species of *Taxus* allow for the production of taxanes and paclitaxel thereof at a yield of 1 to 25 µg/L.

15

In accordance with the present invention, the bacteria isolated from different species of *Taxus* may be employed for the biotransformation of pro-taxanes.

Isolation of the different microorganisms producing taxanes and paclitaxel

Each plant was divided into 5 parts; needles, twigs, stems, bark and roots. Each inner part of the
5 plant was verified for the presence of taxanes and paclitaxel producing microorganisms.

The surface of every part of the plant was sterilized with 95% ethanol and then, cut into small pieces with a sterile blade. Pieces were homogenized in sterile water with a POLYTRON™ that had also been sterilized with ethanol 95%. The resulting mix was used to inoculate two different culture media; R2A agar (Difco) and Sabouraud agar (Difco).
10

Each plate was incubated at 22°C and examined on
15 a day-to-day basis. The morphology of each colony was meticulously noted and the bacteria were transferred on different media until a pure culture was obtained. A Gram coloration of every bacteria was done before the culture was frozen at -80°C.

Over 50 bacteria were isolated from different
20 samples of *Taxus canadensis* of the province of Quebec. In addition, over 30 different bacteria were isolated from different species of *Taxus* which include, without limitations, *Taxus brevifolia*, *T. baccata*, *T. cuspidata*, *T. hunnewelliana*. Some of them, showing taxanes
25 and paclitaxel production capacities, will be fully described below.

Screening of microorganisms

In order to verify the production of taxanes and
30 paclitaxel by microorganisms, each organism was cultured in at least 500 ml of a growth supporting nutrient medium. Any liquid medium allowing taxanes and

paclitaxel thereof production may be employed. Exemplary liquid media are S-7 media (Table 2), and defined media for *Bacillus* (Table 3). Every culture was performed in culture flasks and incubated at a temperature ranging from 20°C to 35°C with constant shaking until a sufficient growth was achieved, generally 18 to 72 hres.

Table 2
Composition of S-7 medium

| Compounds | g/L |
|---|--------|
| glucose | 1 |
| fructose | 3 |
| sucrose | 6 |
| sodium acetate | 1 |
| soytone | 1 |
| thiamine | 0,001 |
| biotine | 0,001 |
| pyridoxal-HCl | 0,001 |
| Ca pantothenate | 0,001 |
| MgSO ₄ | 0,0036 |
| CaNO ₃ | 0,0065 |
| Cu(NO ₃) ₂ | 0,001 |
| ZnSO ₄ | 0,0025 |
| MnCl ₂ | 0,005 |
| FeCl ₃ | 0,002 |
| phenylalanine | 0,005 |
| sodium benzoate | 0,1 |
| KH ₂ PO ₄ 1M (pH 6,8) | 1 ml |

Table 3
Composition of the defined medium for *Bacillus*

| Compounds | g/L |
|--------------------------------------|------|
| L-glutamic acid | 10 |
| glucose | 5 |
| citric acid | 1 |
| K ₂ HPO ₄ | 0,5 |
| KH ₂ PO ₄ | 0,5 |
| MgSO ₄ -7H ₂ O | 0,2 |
| MnSO ₄ -4H ₂ O | 0,01 |
| FeSO ₄ -7H ₂ O | 0,01 |

The culture was then centrifuged and the pellet
5 separated from the supernatant by decantation. To ver-
ify if taxanes and paclitaxel were secreted in the
medium or if it was confined within the cells, both
were tested for the presence of the drug. Since tax-
anes and paclitaxel are hydrophobic, and in order to
10 concentrate each sample, an extraction with an organic
solvent was performed. For the pellet, the cells were
dried and about 200 mg were powdered and ultrasonicated
twice for 40 minutes in 3 ml methanol. The extracts
were dried at 25°C. The residue was dissolved by add-
15 ing 2 ml of methylene chloride and 2ml of distilled
water. After appropriate shaking, the mixture was cen-
trifuged at 4 000 rpm for 5 min. The methylene chlo-
ride fraction was collected and dried under reduced
pressure. Finally, the residue is dissolved in 0,5 ml
20 of HPLC grade methanol.

The supernatant is extracted with one volume of
methylene chloride. After appropriate shaking, the

organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in 50 ml of methylene chloride and 50 ml of distilled water. After appropriate shaking, each fraction was collected and dried under reduced pressure. Each residue is dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C.

a) HPLC screening

10 HPLC method no. 1

Some extracts were analyzed by High Performance Liquid Chromatography (HPLC) on a system consisting of a WATERS™ 625 LC pump, a WATERS™ 996 photodiode array spectrophotometer, and a WATERS™ 717plus autosampler. Chromatography was performed with a phenyl column from Waters (5µm particle size, 6 mm X 15 mm) with a guard module. The injection volume varies from 50 to 150 µl and the flow rate maintained at 1 ml/min. The following elution program was used;

20 0 to 20 min.: methanol:water:acetonitrile
(20:65:15) ramped to methanol:water:acetonitrile
(20:45:35)
20 to 50 min.: methanol:water:acetonitrile (20:45:35)
ramped to methanol:water:acetonitrile
25 (20:25:55)
50 to 60 min.: methanol:water:acetonitrile (20:25:55)
ramped to methanol 100%

Table 4 identifies the retention times of known authentic standards on HPLC methods no. 1 and no. 2. Using HPLC no. 1, paclitaxel has a retention time of 46 minutes. In Fig. 1, we show the ultraviolet spectrum

of paclitaxel produced by *Sphingomonas taxi*. The spectrum is very characteristic with a second maximum of absorption at 230nm. This figure illustrates that *Sphingomonas taxi* produces a compound having the same retention time and the same UV spectrum as paclitaxel.

HPLC method no. 2

Some extracts were analyzed on the same HPLC system with a curosil-PFP column (250 mm X 3.2 mm) from Phenomenex with a guard module. Injections varied from 50 ul to 150 ul and the flow rate maintained at 0.8 ml/min. The following gradient program was used;

0 to 50 min.: acetonitrile:water (25:75) ramped to
acetonitrile:water (65:35)

50 to 62.5 min.: acetonitrile:water (65:35) ramped to
methanol 100%

62.5 to 65 min.: methanol 100% to acetonitrile:water
(25:75)

65 to 75 min.: acetonitrile:water (25:75)

As shown in Table 4, using HPLC method no. 2, paclitaxel is eluted at 36.987 minutes.

Table 4

Retention time of taxanes standards using HPLC methods
no. 1 and no. 2

| Taxanes | Retention time using | |
|---|----------------------|-------------------|
| | HPLC method no. 1 | HPLC method no. 2 |
| 10-deacetyl baccatin III | n/a | 12.037 min. |
| baccatin III | n/a | 20.670 min. |
| 7-xylosyl-10-deacetyltaxol B | n/a | 24.870 min. |
| 7-xylosyl-10-deacetyltaxol and taxinine M | n/a | 27.120 min. |
| 7-xylosyl-10-deacetyltaxol C | n/a | 28.770 min. |
| 10-deacetyltaxol and 7-xylosyltaxol | n/a | 30.770 min. |
| cephalomannine | n/a | 34.753 min. |
| 7-epi-10-deacetyltaxol | n/a | 35.703 min. |
| paclitaxel | 46 minutes | 36.987 min. |
| taxol C | n/a | 38.853 min. |
| 7-epitaxol | n/a | 42.287 min. |

5 Fig. 2A shows a typical chromatogram of an
organic extract of *Bacillus cereus* ssp. *taxi*, and in
Figs. 2B and 2C there is compared the UV spectra of the
substances produced by *Bacillus* with authentic commer-
cial plant standards. This figure clearly illustrates
10 the ability of *Bacillus cereus* ssp. *taxi* to produce
paclitaxel and 7-xylosyl-10-deacetyltaxol.

Fig. 3A shows the typical HPLC chromatogram of
the supernatant of *Pantoea* sp. BCM 1 and, in Fig. 3B
there is compared the bacterial 7-epi-10-deacetyltaxol
15 against an authentic commercial plant standard, estab-
lishing the production of 7-epi-10-deacetyltaxol by
Pantoea sp. BCM 1.

Fig. 4A shows a typical chromatogram of *Bacillus*
megaterium ssp. *taxi* and, in Fig. 4B there is compared
20 the ultraviolet spectrum of the bacterial paclitaxel

with an authentic standard proving the capacity of this bacterium to produce paclitaxel.

Fig. 5A shows a typical chromatogram of *Bacillus cereus* ssp. BCM 4 and, Fig 5B shows a substance having
5 the characteristic ultraviolet spectrum of a taxane compared to a standard of 7-xylosyl-10-deacetyltaxol co-eluting with taxinine M, proving the capacity of *Bacillus cereus* ssp. BCM 4 to produce taxanes.

b) Cytotoxicity on cancer cells

10 An ovarian cancer cell line obtained from American Type Culture Collection (12301 Parklawn Drive, Rockville, MD 20852 USA) under ATCC accession number CRL-1572) was chosen for the investigation. Briefly, 2 000 cells/well of a 96-well microplate were inoculated.
15 After 2 days, different dilutions of the drug were added in a volume of 100 μ l. Three days later, the viability of cells was measured with ALAMAR™ blue (B. Pagé et al. 1993, *Intl. J. of Oncology*, **3**:473-476). The ATCC CRL-1572 cell line is particularly sensitive
20 to paclitaxel (ID_{50} of 1 ng/ml). Microbial extracts have also been tested for their cytotoxicity on those cells. Fig. 6 shows the cytotoxicity of different bacterial supernatant extracts. This figure clearly demonstrates that culture supernatant extracts from *Sphingomonas taxi* and *Bacillus cereus* ssp. *taxi* are at least
25 5-fold more cytotoxic than extracts from non-paclitaxel producing bacteria such as STJ.BRP.K1 and *E. coli* TG1.

c) Mass spectrometry

30 Mass spectrometry of the substances eluted between 45 and 48 minutes with HPLC method no.1 from an

extract of *Sphingomonas taxi* was performed. Fig. 7A shows the results obtained. In every sample, a substance with a molecular weight (M.W.) of 853,5 daltons appears. The theoretical M.W. of paclitaxel is 854 daltons. Even if these extracts were partially purified, essentially the major compound obtained is paclitaxel.

d) Characterization of a bacterial taxane by EI/MS

Fig. 9A, shows a typical chromatogram of *Bacillus cereus* ssp. *taxi* producing a characteristic taxane having a retention time of 15 minutes using HPLC method no. 2. In Fig. 9B, the characteristic ultraviolet spectrum of this substance is illustrated. It was purified on HPLC using HPLC method no. 2 and, analyzed in Electro Ionization Mass Spectrometry (EI/MS) as described by Thomas D. McClure et al. (*J. Am. Soc. Mass Spectrom.*, 1992, **3**, pp. 672-679).

Fig. 10A shows the EI spectrum of this taxane and Fig. 10B shows the characteristic fragments of this taxane. Since this taxane has never been observed in plant extracts of different species of *Taxus*, and this compound is produced by at least two species of *Bacillus* (*cereus* ssp. *taxi* and *megaterium* ssp. *taxi*), we consider this novel taxane unique to microorganisms isolated from *Taxus*.

Characterization of taxane and paclitaxel producing microorganisms

a) Biochemical and physiological characteristics

Table 5 shows the species of *Taxus* from which each bacterium was isolated, the Gram coloration, the

morphology of colonies on different culture media and, some biochemical characteristics. This Table clearly illustrates the diversity of our taxanes and paclitaxel producing bacteria i.e. we have isolated and identified

5 Gram-negative and Gram-positive rods including Actinomyces from different species of *Taxus* which all possess taxanes and/or paclitaxel producing capacities.

Table 5

Cellular, morphological and biochemical characteristics
of some taxanes and paclitaxel producing bacteria

| Name | Isolated from | Gram | Cellular morphology | Description of colonies on blood agar | Description of colonies on TA-1 | Catalase | Urease |
|---------------------------------------|----------------------------|------|---------------------|--|---|----------|--------|
| <i>Sphingomonas taxi</i> | <i>Taxus canadensis</i> | - | Rod | No growth | 3 days to grow Orange-Opaque Glossy-Convex Circular contour | + | - |
| <i>Bacillus cereus ssp. taxi</i> | <i>Taxus canadensis</i> | + | Rod | Double hemolysis Gray-green- Opaque Dry-Dull-Flat Irregular edge | Cream- Opaque Dry-Dull-Flat Irregular edge | + | - |
| <i>Bacillus megaterium ssp. taxi</i> | <i>Taxus hunnewelliana</i> | + | Rod | Gray- Opaque Dry-Dull Convex Irregular edge | Cream- Opaque Glossy Slightly convex Irregular edge | + | - |
| <i>Pantoea sp. BCM 1</i> | <i>Taxus hunnewelliana</i> | - | Rod | Semi-translucent Glossy-Flat Regular edge | Cream with yellow pigment in middle Opaque-Glossy- Flat Regular edge | + | - |
| <i>Pantoea sp. BCM 2</i> | <i>Taxus cuspidata</i> | - | Rod | Yellow Opaque Glossy-Flat Regular edge | Yellow Semi-translucent Glossy-Flat Regular edge | + | - |
| <i>Pantoea sp. BCM 3</i> | <i>Taxus cuspidata</i> | - | Rod | Semi-translucent Glossy-Flat Regular edge | Yellow Semi-translucent Glossy-Flat Regular edge | + | - |
| <i>Bacillus cereus ssp. BCM 4</i> | <i>Taxus brevifolia</i> | + | Rod | Double hemolysis Gray-green- Opaque Dry-Dull-Flat Irregular edge | Cream- Opaque Dry-Dull-Flat Irregular edge | + | - |
| <i>Bacillus subtilis ssp. taxi</i> | <i>Taxus baccata</i> | + | Rod | Semi-translucent Dry, Dull Convex Regular edge | Cream- Translucent Dry, Dull Convex Regular edge | + | - |
| <i>Bacillus megaterium ssp. BCM 9</i> | <i>Taxus hunnewelliana</i> | + | Rod | Gray- Opaque Dry-Dull Convex Irregular edge | Cream- Opaque Glossy Slightly convex Irregular edge | + | - |
| <i>Curtobacterium sp. BCM 5</i> | <i>Taxus brevifolia</i> | + | Rod | 2 days to grow Cream Semi-translucent Glossy-Flat Regular edge | 2 days to grow Yellow Semi-translucent Glossy-Flat Regular edge | + | - |
| <i>Sphingomonas sp. BCM 7</i> | <i>Taxus hunnewelliana</i> | - | Rod | No growth | 3 days to grow Orange-Opaque Glossy-Convex Regular edge | + | - |

5

b) Identification of the genus of taxanes and
paclitaxel producing microorganisms

The genus of each taxanes and paclitaxel producing bacteria was determined by sequencing the 16S

rRNA genes. Genomic DNA of each strain was used as template for PCR (Polymerase Chain Reaction). Primers based on conserved regions at the beginning and the end of the 16S rRNA gene, SSU-27 (5'-AGAGTTTGATCMTGGCTCAG-3'; SEQ ID NO:12), and SSU-1 492 (5'-TACGGYTACCTTGTTACGACTT-3'; SEQ ID NO:13), were used to amplify a portion of the 16S gene. The amplicons were purified with the "PCR purification kit" (sold by Qiagen) and sequenced using the ABI Prism System. Sequence analysis was performed using GCG software package (Genetics Computer Group Inc., Madison, WI).

Fig. 8A shows the almost complete sequence of the 16S rRNA gene of *Sphingomonas taxi*. Since this strain has unique biosynthetic capacities and more than 3% sequence difference with the 16S rRNA genes of other known species of *Sphingomonas*, we created a new species and named it *taxi* on the behalf of its isolation source. Fig. 8B shows the almost complete sequence of the 16S rRNA gene of *Bacillus cereus* ssp. *taxi*. Since this bacterium possesses unique metabolic capacities, and in order to differentiate this species from other known *Bacillus cereus*, we identified it by subspecies name *taxi* also on the behalf of its isolation source. In Figs. 8C to 8L, we show partial sequences of the 16S rRNA genes of other taxanes and/or paclitaxel producing microorganisms.

Consequently, in accordance with the present invention, a plurality of bacteria isolated from different species of *Taxus* can be used for the mass production of paclitaxel and other taxanes. Based on the analysis of partial 16S rRNA gene sequences, and morphological and biochemical characteristics, we assigned

the following genera, species, and subspecies or strain names to our paclitaxel and taxanes producing bacterial isolates; *Sphingomonas taxi*, *Bacillus cereus* ssp. *taxi*, *Bacillus megaterium* ssp. *taxi*, *Pantoea* sp. BCM 1, *Pantoea* sp. BCM 2, *Pantoea* sp. BCM 3, *Bacillus cereus* ssp. BCM 4, *Bacillus subtilis* ssp. *taxi*, *Bacillus megaterium* ssp. BCM 9, *Curtobacterium* sp. BCM 5 and *Sphingomonas* sp. BCM 7.

10 **Biotransformation of taxanes**

a) **Preparation of an aqueous extract of *Taxus canadensis***

Fresh cuttings of needles and small twigs (10 g) of a sample of *Taxus canadensis* are homogenized in 100 ml of distilled water. The solution is then centrifuged at 7 000 rpm and the clear supernatant sterilized by filtration on a 0,22 µm filter. The solution is kept frozen at -20°C until utilization.

20 b) **Biotransformation of taxanes by taxanes and paclitaxel producing bacteria**

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus canadensis*. This resulting supplemented medium is then inoculated with a thawed vial of a pure culture of one of our strain and incubated at 30°C with constant shaking for a time sufficient to allow biotransformation of pro-taxanes.

The culture is then centrifuged and the remaining supernatant extracted with one volume of methylene chloride or ethyl acetate. After appropriate shaking, the organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in

50 ml of methylene chloride or ethyl acetate, and 50 ml of distilled water. After appropriate shaking, each fraction was collected and dried under reduced pressure. Each residues is dissolved in a measured minimal
5 volume of HPLC grade methanol. All samples were kept frozen at -20°C until analysis.

Samples were analyzed on HPLC using method no. 2. Fig. 11 shows the evolution of two taxanes in A) the sterile culture medium S-7 supplemented with 1% v/v
10 of an aqueous extract of *Taxus canadensis* shaken at 150 rpm and incubated at 30°C, and in B) the supernatant of *Sphingomonas taxi* cultured in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis* shaken at 150 rpm and incubated at 30°C.
15 This figure clearly illustrates that in the supernatant of *Sphingomonas taxi*, the diminution of the taxane eluted at 12 minutes corresponds to the proportional elevation of the taxane eluted at 24 minutes, proving the capacity of *Sphingomonas taxi* to biotransform tax-
20 anes.

In addition, Fig. 12 compares the HPLC chromatogram of the organic extract of the culture supernatant of *S. taxi* incubated 24, 48 and 72 hours in the culture medium S-7 supplemented with 1% v/v of an aque-
25 ous extract of *Taxus canadensis*. This Fig. 12 clearly illustrates the production of pro-taxanes. The ultra-violet spectrum of one of these pro-taxanes is illustrated in Fig. 14A. Fig. 14A compares the UV spectrum of the new biotransformed taxane produced by *S. taxi*
30 with taxanes from the aqueous extract of *Taxus canadensis*.

Mutagenesis of taxanes and paclitaxel producing bacteria

Typically, 20 ml of the culture medium TA-1 with 200 µg/ml of daunorubicin (purchased from Rhône-Poulenc) were inoculated with 500 µl of an overnight culture. The resulting broth was incubated at 200 rpm at 30°C for 2 days. After this time 10 ml of the broth are added to 10 ml of fresh medium containing 200 µg/ml of daunorubicin and incubated as described above. The preceding step is repeated as necessary to obtain mutated bacteria. Those mutants were further isolated on the solid culture medium TA-1 (composition as follows).

Solid culture medium TA-1

| Ingredient | amount |
|------------------|--------|
| glucose | 5 g |
| tryptone | 20 g |
| yeast extract | 5 g |
| NaCl | 0.5 g |
| agar | 15 g |
| H ₂ O | 1 L |

15

Biotransformation of taxanes by mutated strains

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus canadensis*. This resulting supplemented medium is then inoculated with a thawed vial of a pure culture of one of our strain and incubated at 30°C with constant shaking for a time sufficient to allow biotransformation of pro-taxanes.

The culture is then centrifuged and the remaining supernatant extracted with one volume of methylene

25

chloride or ethyl acetate. After appropriate shaking, the organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in 50 ml of methylene chloride or ethyl acetate, and 50 ml of distilled water. After appropriate shaking, each fraction was collected and dried under reduced pressure. Each residue is dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C until analysis.

10 Samples were analyzed on HPLC using method no. 2. Fig. 13 shows HPLC chromatograms of *S. taxi*, *S. taxi* D200 and *S. taxi* D201 incubated the same time (48 hours) in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*. All cultures had comparable cell density. This figure clearly illustrates the improved yields of biotransformation by the mutated strains *S. taxi* D200 and *S. taxi* D201. In Figs. 14B and 14C the characteristic ultra-violet spectrum of the new pro-taxanes, produced by the mutated strains *S. taxi* D200 and *S. taxi* D201, are compared with the UV spectrum of two taxanes from *Taxus canadensis*.

25 The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather to limit its scope.

EXAMPLE I

Mass production of paclitaxel using *Sphingomonas taxi*

30 A colony of a pure culture of *Sphingomonas taxi* is used to inoculate 5 ml of S-7 culture medium. The broth is incubated 2-3 days with constant shaking (90 rpm) at 22°C. This 5 ml is then transferred into 5

liters of the same culture medium. The resulting broth is incubated as described above in aerobic conditions.

After 4-5 days of incubation, or after the maximum cell density is reached, the cell pellet is separated by centrifugation. Hydrophobic compounds are then extracted from the supernatant by partition with one volume of dichloromethane. Each organic fraction is evaporated to dryness and, the residue is solubilized in a minimal amount of HPLC grade methanol, typically 500 μ l to 1 ml.

Paclitaxel and taxanes are further purified by HPLC on a phenyl column using HPLC method no. 1. Typically, up to 400 μ l of the methanolic solution are injected and fractions of 0,5 ml to 1 ml are collected. Fractions containing paclitaxel or taxanes are evaporated to dryness.

Using this method, from 200 ng to 1 μ g of paclitaxel per liter of culture medium were purified.

20

EXAMPLE II

Mass production of taxanes and paclitaxel using *Bacillus cereus* ssp. *taxi*

A thawed vial of a pure dense cell suspension of *Bacillus cereus* ssp. *taxi* is used to inoculate 500 ml of the defined medium for *Bacillus*. The broth is incubated 1 to 3 days with constant shaking (150 rpm) at 30°C. The cell pellet is then separated from the supernatant by centrifugation. Hydrophobic substances are extracted from the supernatant by an extraction with one volume of dichloromethane. The organic fraction is evaporated to dryness under reduced pressure,

and residues resolubilized in a minimal amount of HPLC grade methanol.

Taxanes and paclitaxel are further purified on HPLC using method no. 2. Using this method, from 0,2 to 10 µg of paclitaxel can be produced, and from 0,2 to 15 µg of taxanes, including the specific bacterial taxane illustrated in Fig. 13B, can also be produced.

EXAMPLE III

10 Mass production of taxanes and paclitaxel using *Bacillus megaterium* ssp. *taxi*

A thawed vial of a pure dense cell suspension of *Bacillus megaterium* ssp. *taxi* is used to inoculate 500 ml of the S-7 culture medium. The broth is incubated 1 to 3 days with constant shaking (150 rpm) at 30°C. The cell pellet is then separated from the supernatant by centrifugation. Hydrophobic substances are extracted from the supernatant by an extraction with one volume of dichloromethane. The organic fraction is evaporated to dryness under reduced pressure, and residues resolubilized in a minimal amount of HPLC grade methanol.

Taxanes and paclitaxel are further purified on HPLC using method no. 2. Using this method, from 1 to 12 µg of paclitaxel can be produced, and from 1 to 15 µg of taxanes, including the specific bacterial taxane illustrated in Fig. 13B, can also be produced.

EXAMPLE IV

30 Biotransformation of pro-taxanes by *Sphingomonas taxi*

The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus*

canadensis. This resulting supplemented medium is then inoculated with a thawed vial of a pure culture of one of *Sphingomonas taxi* and incubated at 30°C with constant shaking for 24 to 96 hours.

5 The culture is then centrifuged and the remaining supernatant extracted with one volume of methylene chloride. After appropriate shaking, the organic fraction is evaporated to dryness under reduced pressure. The residue is then resolubilized in 50 ml of methylene
10 chloride and 50 ml of distilled water. After appropriate shaking, the organic fraction is collected and dried under reduced pressure. The residue is dissolved in 500µl of HPLC grade methanol and 100 µl of the methanolic solution are analyzed on HPLC using method
15 no. 2 and compared to the resulting chromatogram of the organic extract of the growth-supporting nutrient medium supplemented with and aqueous extract of *Taxus canadensis* 1% v/v shaken the same time.

 As illustrated in Figs. 11, 12 and 14A, *Sphingomonas taxi* is able to biotransform taxanes into new
20 pro-taxanes.

EXAMPLE V

Mutagenesis of *Sphingomonas taxi*

25 20 ml of the culture medium TA-1 with 200 µg/ml of daunorubicin (purchased from Rhône-Poulenc) were inoculated with 500 µl of an overnight culture of *Sphingomonas taxi*. The resulting broth was incubated at 200 rpm at 30°C for 2 days. After this time 10 ml
30 of the broth are added to 10 ml of fresh medium containing 200 µg/ml of daunorubicin and incubated as described above. The preceding step is repeated as necessary to obtain mutated bacteria. Those mutants were further isolated on the solid culture medium TA-1. Two

new mutated strains were obtained named *Sphingomonas taxi* D200 and *Sphingomonas taxi* D201.

EXAMPLE VI

5 **Biotransformation of taxanes by *Sphingomonas taxi* D200 and *Sphingomonas taxi* D201**

 The growth supporting nutrient medium S-7 is supplemented with 1% v/v on an aqueous extract of *Taxus canadensis*. This resulting supplemented medium is then
10 inoculated with a thawed vial of a pure culture of one of our mutated strain and incubated at 30°C at 150 rpm. Cultures were stopped after 24, 48 and 72 hours of incubation.

 Cultures were then centrifuged and the remaining
15 supernatants extracted with one volume of ethyl acetate. After appropriate shaking, the organic fractions were evaporated to dryness under reduced pressure. Residues were then resolubilized in 50 ml of ethyl acetate. After appropriate shaking, fractions
20 were collected and dried under reduced pressure. Each residues were dissolved in a measured minimal volume of HPLC grade methanol. All samples were kept frozen at -20°C until analysis.

 Samples were analyzed on HPLC using method no.
25 2. Fig. 13 shows HPLC chromatograms of *S. taxi*, *S. taxi* D200 and *S. taxi* D201 incubated the same time (48 hours) in the culture medium S-7 supplemented with 1% v/v of an aqueous extract of *Taxus canadensis*. All cultures had comparable cell densities. This figure
30 clearly illustrates the improved yields of biotransformation by the mutated strains *S. taxi* D200 and *S. taxi* D201. In Fig. 14B the characteristic ultraviolet spec-

trum of the new pro-taxanes produced by *S. taxi* D200 is compared with the UV spectrum of two taxanes from *Taxus canadensis*. Fig. 14C compares the UV spectrum of the new biotransformed taxane produce by *S. taxi* D201 with
5 taxanes from the aqueous extract of *Taxus canadensis*.

While the invention has been described in connection with specific embodiments thereof, it will be understood that is capable of further modifications and this application is intended to cover any variations,
10 uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as many be applied to
15 the essential features hereinbefore set forth, and as follows in the scope of the appended claims.



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: 301-231-5519 or 231-5532 • FAX: 301-816-4366

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

BCM Developpement Inc.
Attn: Nathalie Landry
125 rue Dalhousie, suite 218
Quebec Canada G1K 4C5

REC'D 30 MAR 1999

WIPO PCT

Deposited on Behalf of: BCM Developpement

Identification Reference by Depositor:

ATCC Designation

| | |
|--------------------------------------|--------|
| <i>Bacillus cereus</i> ssp. taxi | 202061 |
| <i>Bacillus megaterium</i> ssp. taxi | 202062 |
| <i>Curtobacterium</i> sp. BCM5 | 202063 |
| <i>Pantoea</i> sp. BCM2 | 202064 |
| <i>Bacillus megaterium</i> BCM9 | 202065 |
| <i>Bacillus cereus</i> BCM4 | 202066 |

The deposits were accompanied by: a scientific description X a proposed taxonomic description indicated above. The deposits were received December 12, 1997 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: X We will not inform you of requests for the strains.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested December 18, 1997. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Barbara M. Hailey, Administrator, Patent Depository

Date: December 18, 1997

cc: France Cote



American Type Culture Collection

12301 Parklawn Drive • Rockville, MD 20852 USA • Telephone: 301-231-5519 or 231-5532 • FAX: 301-816-4366

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

BCM Developpement Inc.
Attn: Nathalie Landry
125 rue Dalhousie, suite 218
Quebec Canada G1K 4C5

Deposited on Behalf of: BCM Developpement

Identification Reference by Depositor:

ATCC Designation

| | |
|------------------------------------|--------|
| <i>Sphingomonas</i> taxi D201 | 202067 |
| <i>Sphingomonas</i> taxi D200 | 202068 |
| <i>Sphingomonas</i> sp. BCM7 | 202069 |
| <i>Pantoea</i> sp. BCM3 | 202070 |
| <i>Pantoea</i> sp. BCM1 | 202071 |
| <i>Bacillus subtilis</i> ssp. taxi | 202072 |

The deposits were accompanied by: ☐ a scientific description ☒ a proposed taxonomic description indicated above. The deposits were received December 12, 1997 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: ☒ We will not inform you of requests for the strains.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested December 18, 1997. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Barbara M. Hailey
Barbara M. Hailey, Administrator, Patent Depository

Date: December 18, 1997

cc: France Cote

WHAT IS CLAIMED IS:

1. A process for producing a taxane, which comprises the steps of:

- a) culturing at least one bacteria isolated from plant species of *Taxus* in growth-supporting nutrient medium capable of promoting growth and reproduction of said bacteria, and wherein said culturing is effected for a time sufficient to allow production of a taxane; and
- b) recovering a taxane from said bacteria or medium of step a).


2. The process of claim 1, wherein the plant species of *Taxus* is of the species selected from the group consisting of but not limited to *Taxus canadensis*, *T. brevifolia*, *T. baccata*, *T. hunnewelliana* or *T. cuspidata*.

3. The process of claim 1, wherein said bacteria is of the genus selected from the group consisting of *Sphingomonas*, *Bacillus*, *Pantoea*, and *Curtobacterium*.

4. The process of claim 1, wherein said taxane produced is paclitaxel.

5. The process of claim 1, wherein said taxane is selected from the group consisting of paclitaxel, 10-deacetylcephalomannine, 7-epitaxol, 10-deacetyl-7-epitaxol, 7-epicephalomannine, baccatin III, 10-deacetyl-baccatin III, cephalomannine, 7-epibaccatin III, 7-

xylosyltaxol, 7-xylosyl-cephalomannine, taxagifine, δ -benzoyloxy taxagifine, 9-acetyloxy taxusin, 9-hydroxy taxusin, taxane Ia, taxane Ib, taxane Ic, taxane Id and any taxane corresponding to Formula I:



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} are defined in Table 1.

Table 1

| Compound | R ₁ ⁽¹⁾ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ ⁽³⁾ | R ₇ ⁽²⁾ | R ₈ R ₁₇ | R ₉ R ₁₀ ⁽⁴⁾ | R ₁₁ | R ₁₂ ⁽⁶⁾ | R ₁₃ | R ₁₄ | R ₁₅ ⁽⁵⁾ | R ₁₆ |
|-----------------------------------|-------------------------------|-------------------|----------------|----------------|----------------|-------------------------------|-------------------------------|--------------------------------|---|----------------------------------|--------------------------------|-----------------|-----------------|--------------------------------|-------------------|
| 1) pacitaxel | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 2) 10-deacetyl- cephalomannine | ceph | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 3) 7-epitaxol | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 4) 10-deacetyl-7- epitaxol | tax | CH ₃ | H | β-OH | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 5) 7-epi- cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 6) baccatin III | α-OH | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 7) 10-deacetyl baccatin III | α-OH | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 8) cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 9) 10-deacetyl taxol | tax | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 10) 7-xylosyl taxol | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-xylosyl | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 11) 7-xylosyl- cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-xylosyl | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 12) taxagifine | =O | α-CH ₃ | β-OH | β-acetyloxy | α-acetyloxy | β-CH ₃ | β-acetyloxy | H | α-cinnamoyloxy | methylene (=CH ₂) | α-acetyloxy | β-H | H | cyclo | α-CH ₃ |
| 13) δ-benzoyloxy- taxagifine | =O | α-CH ₃ | β-OH | β-acetyloxy | α-acetyloxy | β-benzoyl- oxymethyl | β-acetyloxy | H | α-cinnamoyloxy | methylene (=CH ₂) | α-acetyloxy | β-H | H | cyclo | α-CH ₃ |
| 14) 9-acetyloxy- taxusin | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-acetyloxy | β-CH ₃ | H | H | α-acetyloxy | methylene (=CH ₂) | H | H | H | CH ₃ | CH ₃ |
| 15) 9-hydroxy-taxusin | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-OH | β-CH ₃ | H | H | α-acetyloxy | methylene (=CH ₂) | H | H | H | CH ₃ | CH ₃ |
| 16) taxane Ia | tax | CH ₃ | H | =O | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 17) taxane Ib | taxsub | CH ₃ | H | =O | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 18) taxane Ic | taxsub | CH ₃ | H | =O | =O | β-CH ₃ | α-acetyloxy | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 19) taxane Id | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-acetyloxy | β-CH ₃ | β-acetyloxy | H | α-OH | epoxide | α-acetyloxy | β-OH | H | CH ₃ | CH ₃ |
| 20) 7-epibaccatin III | α-OH | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | oxetane | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |

SUBSTITUTE SHEET (RULE 26)

6. A bacterial taxane having the characterizing ultraviolet spectrum and the specific retention time shown in Fig. 13, and the EI spectrum shown in Fig. 14A.

7. The process of claim 1, wherein the taxane produced having the characterizing ultraviolet spectrum and the specific retention time shown in Fig. 13, and the EI spectrum shown in Fig. 14A.

8. The process of claim 1, wherein the bacteria is *Bacillus cereus* ssp. *taxi*.

9. The process of claim 1, wherein the bacteria is *Bacillus megaterium* ssp. *taxi*.

10. The process of claim 1, wherein the bacteria is *Pantoea* sp. BCM 1.

11. The process of claim 1, wherein the bacteria is *Pantoea* sp. BCM 2.

12. The process of claim 1, wherein the bacteria is *Pantoea* sp. BCM 3.

13. The process of claim 1, wherein the bacteria is *Bacillus cereus* ssp. BCM 4.

14. The process of claim 1, wherein the bacteria is *Bacillus subtilis* ssp. *taxi*.

15. The process of claim 1, wherein the bacteria is *Bacillus megaterium* ssp. BCM 9.


16. The process of claim 1, wherein the bacteria is *Curtobacterium* sp. BCM 5.

17. The process of claim 1, wherein said growth-supporting nutrient medium include carbon sources, nitrogen sources, amino acids, vitamins and minerals.

18. A process for producing biotransformed taxanes, which comprises the steps of:

- a) culturing at least one bacteria isolated from plant species of *Taxus* in growth-supporting nutrient medium supplemented with pro-taxanes, and wherein said culturing is effected for a time sufficient to allow the biotransformation of pro-taxanes into taxanes; and
- b) recovering at least one from said bacteria or medium of step a).

19. The process of claim 18, wherein said taxane is selected from the group consisting of paclitaxel, 10-deacetylcephalomannine, 7-epitaxol, 10-deacetyl-7-epitaxol, 7-epicephalomannine, baccatin III, 10-deacetyl-baccatin III, cephalomannine, 7-epibaccatin III, 7-xylosyltaxol, 7-xylosyl-cephalomannine, taxagifine, 8-benzoyloxy taxagifine, 9-acetyloxy taxusin, 9-hydroxy taxusin, taxane Ia, taxane Ib, taxane Ic, taxane Id and any taxane corresponding to Formula I :



wherein $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}$ are defined in Table 1,

Table 1

| Compound | R ₁ ⁽¹⁾ | R ₂ | R ₃ | R ₄ | R ₅ | R ₆ ⁽³⁾ | R ₇ ⁽²⁾ | R ₈ R ₉ R ₁₀ ⁽⁴⁾ | R ₁₁ | R ₁₂ ⁽⁶⁾ | R ₁₃ | R ₁₄ | R ₁₅ ⁽⁵⁾ | R ₁₆ |
|-----------------------------------|-------------------------------|-------------------|----------------|----------------|----------------|-------------------------------|-------------------------------|--|-----------------|--------------------------------|-----------------|-----------------|--------------------------------|-------------------|
| 1) pacitaxel | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 2) 10-deacetyl- cephalomannine | ceph | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 3) 7-epitaxol | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 4) 10-deacetyl-7- epitaxol | tax | CH ₃ | H | β-OH | =O | β-CH ₃ | α-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 5) 7-epi- cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 6) baccatin III | α-OH | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 7) 10-deacetyl baccatin III | α-OH | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 8) cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 9) 10-deacetyl taxol | tax | CH ₃ | H | β-OH | =O | β-CH ₃ | β-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 10) 7-xylosyl taxol | tax | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-xylosyl | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 11) 7-xylosyl- cephalomannine | ceph | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | β-xylosyl | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 12) taxagifine | =O | α-CH ₃ | β-OH | β-acetyloxy | α-acetyloxy | β-CH ₃ | β-acetyloxy | H | α-cinnamoyloxy | α-acetyloxy | β-H | H | cyclo | α-CH ₃ |
| 13) 8-benzoyloxy- taxagifine | =O | α-CH ₃ | β-OH | β-acetyloxy | α-acetyloxy | β-benzoyl- oxymethyl | β-acetyloxy | H | α-cinnamoyloxy | α-acetyloxy | β-H | H | cyclo | α-CH ₃ |
| 14) 9-acetyloxy- taxusin | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-acetyloxy | β-CH ₃ | H | H | α-acetyloxy | H | H | H | CH ₃ | CH ₃ |
| 15) 9-hydroxy-taxusin | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-OH | β-CH ₃ | H | H | α-acetyloxy | H | H | H | CH ₃ | CH ₃ |
| 16) taxane Ia | tax | CH ₃ | H | =O | =O | β-CH ₃ | α-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 17) taxane Ib | taxsub | CH ₃ | H | =O | =O | β-CH ₃ | α-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 18) taxane Ic | taxsub | CH ₃ | H | =O | =O | β-CH ₃ | α-acetyloxy | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |
| 19) taxane Id | α-acetyloxy | CH ₃ | H | β-acetyloxy | α-acetyloxy | β-CH ₃ | β-acetyloxy | H | α-OH | α-acetyloxy | β-OH | H | CH ₃ | CH ₃ |
| 20) 7-epibaccatin III | α-OH | CH ₃ | H | β-acetyloxy | =O | β-CH ₃ | α-OH | H | α-acetyloxy | α-benzoyloxy | β-OH | H | CH ₃ | CH ₃ |

SUBSTITUTE SHEET (RULE 26)

20. The process of claim 19, wherein said pro-taxanes are isolated from any species of *Taxus*.

21. The process of claim 19, wherein said pro-taxanes are isolated from *Taxus canadensis*.

22. The process of claim 19, wherein the bacteria is *Bacillus cereus* ssp. *taxi*.

23. The process of claim 19, wherein the bacteria is *Bacillus megaterium* ssp. *taxi*.

24. The process of claim 19, wherein the bacteria is *Pantoea* sp. BCM 1.

25. The process of claim 19, wherein the bacteria is *Pantoea* sp. BCM 2.

26. The process of claim 19, wherein the bacteria is *Pantoea* sp. BCM 3.

27. The process of claim 19, wherein the bacteria is *Bacillus cereus* ssp. BCM 4.

28. The process of claim 19, wherein the bacteria is *Bacillus subtilis* ssp. *taxi*.

29. The process of claim 19, wherein the bacteria is *Bacillus megaterium* ssp. BCM 9.

30. The process of claim 19, wherein the bacteria is *Curtobacterium* sp. BCM 5.

31. A process for isolating taxanes and paclitaxel producing bacteria from a yew tree, which comprises the steps of:

- a) disinfecting the surface of a yew tree plant part with a suitable disinfectant;
- b) cutting and disrupting the disinfected plant part;
- c) leaching out bacteria with an appropriate solvent from the part of step c);
- d) culturing said leached bacteria on a solid growth-supporting nutrient medium for a time sufficient to allow formation of visible isolated colonies; and
- e) screening said isolated colonies for production of taxanes and paclitaxel.

32. The process of claim 31, wherein the disinfectant used is ethanol at concentration varying from 35% to 99%.

33. The process of claim 31, wherein the solvent to leach out bacteria is water.

34. The process of claim 31, wherein the solid growth-supporting nutrient medium for isolating colonies is selected from the group consisting of R2A agar (Difco) and Sabouraud (Difco).

35. The process of claim 31, wherein screening of isolated bacteria for taxanes and paclitaxel production comprises the steps of:

- a) culturing said isolated bacteria in 500 ml of a growth-supporting liquid nutrient medium at temperature ranging from 20 to 35°C with constant shaking until sufficient growth is achieved;
- b) obtaining the culture medium supernatant or the cells and extracting it with appropriate organic solvents selected from methylene chloride and ethyl acetate;
- c) analyzing said organic extracts by a method suitable for detection of taxanes and paclitaxel.

36. The process of claim 35, wherein the method to detect taxanes and paclitaxel in extracts uses HPLC retention times on a hydrophobic chromatographic matrix and ultraviolet spectra to identify taxanes and paclitaxel in comparison with standards.

37. The process of claim 35, wherein the method to detect taxanes and paclitaxel in extracts uses cytotoxicity on cancer cell lines.

38. The process of claim 35, wherein the method to detect taxanes in extracts uses mass spectrometry to identify paclitaxel and taxanes based on molecular weights fragments and/or total molecule.

39. The process of claim 35, wherein the method to detect taxanes and paclitaxel in extracts uses antibodies raised against taxanes and paclitaxel.

40. The process of claim 35, wherein the method to

detect taxanes and paclitaxel uses an *in vitro* assay monitoring interaction of taxanes with tubulin.

41. A process for improving biotransformation of pro-taxanes into taxanes and paclitaxel by taxanes and paclitaxel-producing bacteria comprising the steps of:

- a) culturing bacteria in the presence of a mutagenic agent for a time sufficient to allow mutagenesis; and
- b) selecting said mutants by a change of the phenotype which results in an increased biotransformation of pro-taxanes into taxanes and paclitaxel.

42. The process of claim 41, wherein the mutagenic agent is a chemical agent.

43. The process of claim 41, wherein the chemical agent is daunorubicin or nitrosoguanidine.

44. The process of claim 41, wherein the mutagenic agent is a physical agent selected from gamma radiation or ultraviolet.

45. The process of claim 41, wherein the mutagenic agent is a biological agent.

46. The process of claim 45, wherein the biological agent is a transposon.

47. A method of bacterial biotransformation of pro-taxanes into taxanes and paclitaxel thereof which com-

prises the steps of:

- a) incubating the mutated bacteria obtained according to the process of claim 41 in a nutrient medium, and wherein said incubation is effected in the presence of pro-taxanes for a time sufficient to allow production of taxanes and paclitaxel; and
- b) isolating said produced taxanes and paclitaxel thereof from said culturing medium of step a).

48. The process of claim 43, wherein the bacteria used is *Sphingomonas taxi* D200.

49. The process of claim 43, wherein the bacteria used is *Sphingomonas taxi* D201.

50. The process of claim 43, wherein the mutated bacterium is isolated from a *Taxus* species and is of the genus of *Sphingomonas*, *Bacillus*, *Pantoea* or *Curtobacterium*.

51. A biologically pure culture of a bacteria of genus *Sphingomonas*, *Bacillus*, *Pantoea* or *Curtobacterium*, which is isolated from *Taxus canadensis*, and wherein said bacteria is characterized by the production of taxane and paclitaxel in a culture media.

52. The biologically pure culture of the bacteria of claim 51, which is *Sphingomonas taxi*, *Bacillus cereus* ssp. *taxi*, *Bacillus megaterium* ssp. *taxi*, *Pantoea* sp. BCM 1, *Pantoea* sp. BCM 2, *Pantoea* sp. BCM 3, *Bacillus cereus* ssp. BCM 4, *Bacillus subtilis* ssp. *taxi*, *Bacil-*

lus megaterium ssp. BCM 9 and *Curtobacterium* sp. BCM 5.

53. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus *Sphingomonas*, belonging to the alpha subdivision of Proteobacteria.


54. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus *Bacillus* belonging to the low G+C Gram positive bacteria.

55. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus *Pantoea*, belonging to the gamma subdivision of Proteobacteria.

56. The biologically pure culture of the bacteria of claim 51, wherein the bacteria is of the genus is isolated from a *Taxus* species and is of the genus *Curto-bacterium*, belonging to the Actinomycetes order of the firmicutes.


57. The biologically pure culture of the bacteria of claim 51, wherein said bacteria is mutated and is *Sphingomonas taxi* D200 or *Sphingomonas taxi* D201.

1/26




SUBSTITUTE SHEET (RULE 26)



2/26

FIG. 1B



3/26

FIG. 2A



4/26

FIS-2BFIS-2C

5/26



FIG. 3AFIG. 3B

6/26

FIG. 4AFIG. 4B

SUBSTITUTE SHEET (RULE 26)

7/26



Spectral Table


| # | Retention Time | Source | Spectrum Name | Baseline Correct | Searchable | Traceable |
|---|----------------|----------------|-----------------------|------------------|------------|-----------|
| 1 | 35.820 | B.B. F2 def di | | On | Yes | Yes |
| 2 | 35.703 | 13-mix stds | 7-epi-10-deacetylaxol | On | Yes | Yes |



Spectral Table

| # | Start Wvln | End Wvln | Resolution | Smooth | Derivative | Spline | Lambda Max | Maximum Absorbance |
|---|------------|----------|------------|--------|------------|--------|------------|--------------------|
| 1 | 200 | 350 | 2.4 | None | None | Off | 200.6 | 0.00501 |
| 2 | 200 | 350 | 2.4 | None | None | Off | 200.6 | 0.42673 |

FIG - 5B

8/26

FIG. 6



10/26

60 ATGATTACGC CAAGCTATT T AGGTGACACT ATAGAATACT CAAGCTATGC ATCCAACGCG
120 TTGGGAGCTC TCCCATATGG TCGACCTGCA GGCGGCCGCA CTAGTGATTA GAGTTTGATC
180 CTGGCTCAGA ACGAACGCTG GCGCATGCC TAACACATGC AAGTCGAACG AGATCTTCGG
240 ATCTAGTGGC GCACGGGTGC GTAACGCGTG GGAATCTGCC CTTTGGTTCC GAATAACAGT
300 TGGAAACGAC TGCTAATACC GGATGATGAC GTAAGTCCAA AGATTTATCG CCAGAGGATG
360 AGCCCGCGTA GGATTAGCTA GTTGGTGTGG TAAGAGCGCA CCAAGGCGAC GATCCTTAGC
420 TGGTCTGAGA GGATGATCAG CCACACTGGG ACTGAGACAC GGCCAGACT CCTACGGGAG
480 GCAGCAGTGG GGAATATTGG ACAATGGCG AAGCCTGAT CCAGCAATGC CGCGTGAGTT
540 GATGAAAGCC TTAGGTTGTT AAAGCTCTTT TACCCGGGAA TGATAATGAC AGTACCGGGA
600 GAATAAGCTC CGGCTAACTC CGTGCCAGCA GCCGCGGTAA TACGGAAGGA GCTAGCGTTG
660 TTCGGAATTA CTGGGCGTAA AGCGCACGTA GGCGCCTTTG TAAAGTTAGAG GTGAAAGCCT
720 GGAGCTCAAC TCCAGAAATG CCTTTAAGAC TGCATCGCTT GAATCCAGGA GAGGTGAGTG
780 GAATTCCGAG TGTAGAGGTG AAATTCGTAG ATATTCGGAA GAACACCACT GCGGAAGCGG
840 GCTCACTGGA CTGGTATTGA CGCTGAGGTG CGAAAGCGTG GGGAGCAAAC AGGATTAGAT
900 ACCCTGGTAG TCCACGCCGT AAACGATGAT AACTAGCTGT CCGGGGACTT GGTCTTTGGG
960 TGGCGCAGCT AACGCATTAA GTTATCCGCC TGGGGAGTAC GGCCGCAAGG TTAAAACTCA
1020 AATGAATTGA CCGGGGCCCTG CACAAGCGGT GGAGCATGTG GTTTAATTCC AGCAACGCG
1080 CAGAACCTTA CCAGCGTTTG ACATGTCCGG ACGATTCTCG GAGACAGATC TCTTCCCTTC
1140 GGGGACTGGA ACGCAGGTGC TGCATGGCTG TCGTCAGCTC GTGTCGTGAG ATGTTGGGT
1200 AAGTCCCGCA ACGAGCGCAA CCCTCGCCTT TAGTTACCAT CATTAGTTG GGGACTCTAA
1260 AGGAACCGCC GGTGATAAGC CGGAGGAAGG TGGGATGAC GTCAAGTCCCT CATGGCCCTT
1320 ACGCGCTGGG CTACACACGT GCTACAATGG CCGTGACAGT GGGCAGCAAA CTCGCGAGAG
1380 TGCGCTAATC TCCAAAAGCC GTCTCAGTTC GGATTGTTCT CTGCAACTCG AGAGCATGAA
1440 GGCGGAATCG CTAGTAATCG CGGATCAGCA TGCCGCGGTG AATACGTTCC CAGGCCTTGT
1500 ACACACCGCC CGTCACACCA TGGGAGTTGG GTTCACCCGA AGGCGTTGCG CTAACCTCGTA
1556 AGAGAGGCAG GCGACCACGG TGGGCTTAGC GACTGGGGTG AAGTCGTAAC AAGTA

SUBSTITUTE SHEET (RULE 26)

7:5 - BA

11/26

AGAGTTTGAT CATGGCTCAG GATGAACGCT GGCGGCGTGC CTAATACATG CAAGTCGAGC 60
GAATGGATTA AGAGCTTGCT CTTATGAAGT TAGCGGCGGA CCGGTGAGTA ACACGTGGGT 120
AACTACCCA TAAGACTGGG ATAACCTCCG GAAACCGGG CTAATACCGG ATAATATTT 180
GAACTGCATA GTTCGAAATT GAAAGCGGC TTCGGCTGTC ACTTATGGAT GGACCCGCGT 240
CGCATTAGCT AGTTGGTGAG GTAACGGCTC ACCAAGCGA CGATGCGTAG CCGACCTGAG 300
AGGGTGATCG GCCACACTGG GACTGAGACA CGGCCCAGAC TCCTACGGGA GGCAGCAGTA 360
GGGAATCTTC CGCAATGGAC GAAAGTCTGA CGGAGCAACG CCGCGTGAGT GATGAAGGCT 420
TTCGGGTCGT AAAACTCTGT TGTTAGGGAA GAACAAGTGC TAGTTGAATA AGCTGGCACC 480
TTGACGGTAC CTAACCAGAA AGCCACGGCT AACTACGTGC CAGCAGCCCG CCGTAATACG 540
TAGGTGGCAA GCGTTATCCG GAATTATTGG GCGTAAAGCG CGCGCAGGTG GTTCTCTAAG 600
TCTGATGTGA AAGCCACCG CTCAACCCGT GAGGTCATT GGAAACTGGG AgACTTGAGT 660
GCAGAAAGG AAAGTGGAAT TCCATGTGTA GCGGTGAAAT GCGTAGAGAT ATGGAGGAAC 720
ACCAAGTGGG AAGCGACTT TCTGTCTGT AACTGACACT GAGGCGGAA AGCGTGGGA 780
GCAACACAGGA TTAGATACCC TGGTAGTCCA CGCCGTAAC GATGAGTGCT AAGTGTTAGA 840
GGGTTCCGC CCTTTAGTGC TGAAGTTAAC GCATTAAAGCA CTCCGCCCTGG GGAGTACGGC 900
CGCAAGGCTG AAACTCAAAG GAATTGACGG GGGCCCGCAC AAGCGGTGGA GCATGTGGTT 960
TAATTCGAAG CAACGCGAAG AACCTTACCA GGTCTTGACA TCCTCTGAAA ACTCTAGAGA 1020
TAGAGCTTCT CCTTCGGAG CAGAGTGACA GGTGTTGCAT GGTTCGTCgTC AGCTCGTGTC 1080
GTGAGATGTT GGGTTAAGTC CCGCAACGAG CGCAACCCCTT GATCTTAGTT GCCATCATTA 1140
AGTTGGGCAC TCTAAGGTGA CTGCCGGTGA CACGTGCCAC AATGGACGGT ATGACGTCAA 1200
ATCATCATGC CCTTTATGAC CTGGGCTACA CACGTGCCAC AATGGACGGT ACAAAGAGCT 1260
GCAAGACCGC GAGGTGAGC TAATCTCATA AAACCGTTCT CAGTTCGGAT TGTAGGCTGC 1320
AACTCGCCTA CATGAAGCTG GAATCGCTAG TAATCGCGGA TCAGCATGCC GCGTGAATA 1380
CGTTCCCGG CCTTGTACAC ACCGCCCGTC ACACACGAG AGTTTGTAAAC ACCCGAAGTC 1440
GGTGGGGTAA CCTTTATGGA GCCAGCCGCC TAAGGTGGGA CAGATGATTG GGTGAAGTC 1500
GTAACAAGGT AA 1512

SUBSTITUTE SHEET (RULE 26)

11/26

12/26

| | | | | | | |
|------|-------------|-------------|-------------|-------------|--------------|-------------|
| 60 | AGAGTTTGAT | CCTGGCTCAG | GATGAACGCT | GGCGGCGTGC | CTAATACATG | CAAGTCGAGC |
| 120 | GAAC TGATTA | GAAGCTTGCT | TCTATGACGT | TAGCGGCGGA | CGGTGAGTA | ACACGTGGGC |
| 180 | AACCTGCCCTG | TAAGACTGGG | ATAACTTCGG | GAACCCGAAG | CTAATACCGG | ATAGGATCTT |
| 240 | CTCCTTCATG | GGGGATGATT | GAAAGATGGT | TTCGGCTATC | ACTTACAGAT | GGGCCCGCGG |
| 300 | TGCATTAGCT | AGTTGGTGAG | GTAACGGCTC | ACCAAGGCAA | CGATGCATAG | CCGACCCTGAG |
| 360 | AGGGTGATCG | GCCACACTGG | GACTGAGACA | CGGCCCAAAC | TCCTACGGGA | GGCAGCAGTA |
| 420 | GGGAATCTTC | CGCAATGGAC | GAAAGTCTGA | CGGAGCAACG | CCGCGTGAGT | GATGAAGGCT |
| 480 | TTCGGGTCCT | AAAACCTCTGT | TGTTnGGGA | GAACAAATAC | CAGAGTAACT | GCTTGTTCCCT |
| 540 | TGACGGTACC | TAACCAAGAA | GCCACGGCTA | ACTACTTTCC | AGCAGCCCGG | GTAATACnTA |
| 600 | TGTTGGCAAG | CGTTATCCGG | AATTATTGGG | CGGTTAAAGC | GCGCGCCAGG | CGGTTTCTTA |
| 660 | AGTCTGATGT | GAAAGCCAC | GGCTCAACCG | TGGAGGTC | TTGGAAACTG | GGGAACTTGA |
| 720 | GTGCAGAAGA | GAAAGCGGA | ATTCCACGTG | TAGCGGTGAA | ATGCCGTAGAG | ATGTGGAGGA |
| 780 | ACACCAGTGG | CGAAGCGGC | TTTTTTGGTCT | GTAAC TGACG | CTGAGGCGCG | AAAGCGTGGG |
| 840 | GAGCAAAACAG | GATTAGATAC | CCTGGTAGTC | CACGCCGTAA | ACGATGAGTG | CTAAGTGTTA |
| 900 | GAGGGTTTCC | GCCCTTTAGT | GCTGCAGCTA | ACGCATTAAG | CAC TCCGCCT | GGGGAGTACG |
| 960 | GTGCAAGAC | TGAAACTCAA | AGGAATTGAC | GGGGGCCCCG | ACAAGCGGTG | GAGCATGTGG |
| 1020 | TTTAATTCTGA | AGCAACGCGA | ATAACCTTAC | CAGGTCCTGA | CATCCTCTGA | CAACTCTAGA |
| 1080 | GATAGAGCGT | TCCCCTTCGG | GGGACAGAGT | GACAGGTGGT | GCA TG GTTGT | CGTCAGCTCG |
| 1140 | TGTCgTGAGA | TgTTGGGtTA | AGTCCC GCAA | CGAGCGCAAC | CCTTGATCTT | AGTTGCCAgC |
| 1200 | ATTTAGTTGG | GCACTCTAAG | GTGACTGCCG | GTGACAAACC | GGAGGAAGGT | GGGATGACG |
| 1260 | TCAAATCATC | ATGCCCCCTTA | TGACCTGGGC | TACACACGTG | CTACAATGGA | TGGTACAAAG |
| 1320 | GGCTGCAAGA | CCGCGAGGTC | AAGCCAATCC | CATAAAACCA | TTCTCAGTTC | GGATTGTAGG |
| 1380 | CTGCAACTCG | CCTACATGAA | GCTGGAATCG | CTAGTAATCG | CGGATCAGCA | TGCCGCGGTG |
| 1440 | AATACGTTCC | CGGGCCTTGT | ACACACCGCC | CGTCACACCA | CGAGAGTTTG | TAAACACCCGA |
| 1500 | AGTCGGTGGA | GTAACCGTAA | GGAGCTAGCC | GCCTAAGGTG | GGACAGATGA | TTGGGGGTGAA |
| 1515 | GTCGTAACAA | GGTAA | | | | |

SUBSTITUTE SHEET (RULE 26)



13/26

60 TCGGGACGGT CAGCACACGA GGAGCTTGCT CCTTGGGTGA CGAGTGGCGG ACGGGTGAGT
120 AATGTCTGGG GATCTGCCCG ATAnAGGGGG ATAACCACTG GAAACGGTGG CTAATACCGC
180 ATAACGTGCG AAGACCAAAG AGGGGACCT TCGGGCCTCT CACTATCGGA TGAACCCAGA
240 TGGGATTAGC TAGTAnGCGG GGTAAATGGCC CACCTAGGCG ACGATCCCCTA nCTGGTCTGA
300 GAGGATGACC AGCCACACTG GAACTGAGAC ACGGTCCAnA CTCTACGGG AGGCAGCAGT
360 GGGGAATATT GCACAATGGG CGCAAGCCTG ATGCAGCCAT GCCGCGTGA TGAAGAAGGC
420 CTTCGGGTTG TAAAGTACTT TCAGCGGGGA GGAAGGCGAT GCGGTTAATA ACCCTGTCTGA
480 TTGACGTTCC CCGCAnGAAG AAGCACCGGC TAACTCCGTG CCAGCAGCCG CCGTAATACC
540 GGAGGGTGCA AGCGTTAATC CGGAATTACT GGGCGTAAAG CGCACGCAGG CCGTCTGTTA
600 AGTCAGATGT GAAATCCCCG GGCTTAACCT GGGAACCTGA TTTGAAACTG GCAGGCTTGA
660 GTCTTGTAGA GGGGGGTAGA ATTCCAGGTG TAGCGGTGAA ATGCGTAGAG ATCTGGAGGA
720 ATACCGGTGG CGAAGGCGGC CCCTTGGACA AAGACTGACG CTCAGGTGCG AAAGCGTGGG
780 GAGCAAAACAG GATTAGATAC CCTGGTAGTC CACGCCGTAA ACGATGTCGA CTTGGAGGTT
840 GTTCCCTTGA GGAGTGGCTT CCGGAGCTAA CGCGTTAAGT CGACCGCCTG GGGAGTACGG
900 CCGCAAGGTT AAAATTCAAA TGAATTGACG GGGGCCCCGA CAAGCGGTGG AGCATGTGGT
960 TTAATTGAT GCAACGCGAA GAACCTTACC TACTCTTGAC ATCCAGCGAA CTTGCCAGAG
1020 ATGGATTGGT GCCTTCGGGA ACGCTGAGAC AGGTGCTGCA TGGCTGTCTGT CAGCTCGTGT
1080 TGTGAAATGT TGGGTTAAGT CCGGCAACGA GCGCAACCTT TATCCTTTGT TGCCAGCGAT
1140 TCGGTCGGGA ACTCAAAGGA GACTGCCGGT GATAAACCGG AGGAAGGTGG GGATGACGTC
1200 AAGTCATCAT GGCCCTTACG AGTAGGGCTA CACACGTGCT ACAATGGCGC ATACAAAGAG
1260 AAGCGACCTC GCGAGAGCAA GCGGACCTCA CAAAGTGCGT CGTAGTCCGG ATCGGAGTCT
1320 GCAACTCGAC TCCGTGAAGT CGGAATCGCT AGTAATCGTG GATCAGAATG CCACGGTGAA
1380 TACGTTCCCG GGCCTTGTAC ACACCGCCCG TCACACCATG GGAGTGGGTI GCAAAAGAAG
1440 TAGGTAGCTT AACCTTCGGG AGGCGGCTTA CCACCTTTGTG ATTCACTGACT GGGGTGAAGT
1451 CGTAACAAGT A

735 - 80

SUBSTITUTE SHEET (RULE 26)

14/26

60 AGAGTTTGAT CCTGGCTCAG GATGAACGCT GCGGCGGTGC CTAATACATG CAAGTCGAGC
 120 GAATGGATTG AGAGCTTGCT CTCGAAGAAGT TAGCGCGGA CCGGTAGTA ACACGTGGGT
 180 AACCTGCCCA TAAGACTGGG ATAACCTCCG GAAACCGGG CTAATACCGG ATAAACATTT
 240 GAACTGCATG GTTCGAAATT GAAAGCGGC TTCGGCTGTC ACTTATGGAT GGACCCGCGT
 300 CGCATTAGCT AGTTGGTGAG GTAACGGCTC ACCAAGGCAA CGATGCGTAG CCGACCTGAG
 360 AGGGTGATCG GCCACACTGG GACTGAGACA CGGCCCAGAC TCCTACGGGA GGCAGCAGTA
 420 GGGAACTCTC CGCAATGGAC GAAAGTCTGA CGGAGCAACG CCGCGTGAGT GATGAAGGCT
 480 TTCGGGTCGT AAAACTCTGT TGTAGGGAA GAACAAGTGC TAGTTGAATA AGCTGGCACC
 540 TTGACGGTAC CTAACCAGAA AGCCACGGCT AACTACGTGC CAGCAGCCGC GGTAAATACGT
 600 AGGTGGCAAG CGTTATCCGG AATTATTGG CGTAAAGCG CCGCAGGTGG TTCTTAGGT
 660 CTGATGTGAA AGCCACCGC TCAACCGTGG AGGTCATTG GAAACTGGGA GACTTGAGTG
 720 CAGAAGAGGA AAGTGAATT CCATGTGTAG CCGTGAAATG CGTAGAGATA TGGAGGAACA
 780 CCAGTGGCGA AGGCGACTTT CTGGTCTGTA ACTGACACTG AGCGCGGAAA GCGTGGGAG
 840 CAAACAGGAT TAGATACCCT GGTAGTCCAC GCCGTAAACG ATGAGTGCTA AGTGTTAGAG
 900 GGTTCGCGC CTTTAGTGCT GAAGTTAACG CATTAAGCAC TCCGCCCTGGG GAGTACGGCC
 960 GCAAGGCTGA AACTCAAAGG AATTGACGGG GGCCCGCACA AGCGGTGGAG CATGTGGTTT
 1020 AATTGGAAGC AACGCGAAGA ACCTTACCAG GTCTTGACAT CCTCTGAATA CCCTAGAGAT
 1080 AGGGCTTCTC CTTCGGGAGC AGAGTGACAG GTGGTGCAATG GTTGTCGTCA GCTCGTGTCTG
 1140 TGAGATGTTG GGTAAAGTCC CGCAACGAGC GCAACCCCTTG ATCTTAGTTG CCATCATTA
 1200 GTTGGGCACT CTAAGGTGAC TGCCGGTGAC AAACCGGAGG AAGGTGGGA TGACGTCAA
 1260 TCATCATGYC CCTTATGACC TGGGCTACAC ACGTGCTACA ATGGACGGTA CAAAGAGCTG
 1320 CAAGACCGCG AGGTGGAGCT AATCTCATAA AACCGTTCTC AGTTCrGATT GTAGGCTGCA
 1380 ACTCGCCTAC ATGAAGCTGG AATCGCTAGT AATCGCGGAT CAGCATGCCG CCGTGAATAC
 1440 GTTCCCGGGC CTTGTACACA CCGCCCGTCA CACCACGAGA GTTTGTAAACA CCGGAAGTCG
 1500 GTGGGGTAAC CTTTTTGGAG CCAGCCGCCT AAGGTGGGAC AGATGATTGG GGTGAAGTCG
 1513 TAACAAGGTA GCC

SUBSTITUTE SHEET (RULE 26)



15/26

60 AGAGTTTGAT CCTGGCTCAG GACGAACGCT GCGGCGGTGC CTAATACATG CAAGTCGAGC
 120 GAACAGATGG GAGCTTGCTC CCTGATGTTA GCGGCGGACG GGTGAGTAAC ACGTGGGTAA
 180 CCTGCCCTGTA AGACTGGGAT AACTCCGGGA AATCGGGGCT AATACCGGAT GGTGTTTGA
 240 ACCGCATGGT TCAGACATAA AAGGTGGCTT CCGCTACCAC TTACAGATGG ACCCGCGGCG
 300 CATTAGCTAG TTGGTGAGGT AACGGCTCAC CAAGCGACG ATGCGTAGCC GACCTGAGAG
 360 GGTGATCGGC CACACTGGGA CTGAGACACG GCCCAGACTC CTACGGGAGG CAGCAGTAGG
 420 GAATCTTCCG CAATGGACGA AAGTCTGACG GAGCAACGCC GCGTGAGTGA TGAAGGTTTT
 480 CGGATCGTAA AGCTCTGTTG TTAGGGAAGA ACAAGTGCCG TTCAAATAGG GCGCACCTT
 540 GACGGTACCT AACCAGAAAG CCACGGCTAA CTACGTGCCA GCAGCCGCGG TAATACGTAG
 600 GTGGCAAGCG TTGTCCGGAA TTATTGGGCG TAAAGGCTC GCAGGCGGTT TCTTAAGTCT
 660 GATGTAAAG CCCCCGGTTC AACGGGGAG GGTCAATTGA AACTGGGGAA CTTGAGTGCA
 720 GAAGAGGAGA GTGGAATTCC ACGTGTAGCG GTGAAATGCG TAGAGATGTG GAGGAACACC
 780 AGTGGCGAAG GCGACTCTCT GGTCTGTAAC TGACGCTGAG GAGCGAAAGC GTGGGAGCG
 840 AACAGGATTA GATACCTTGG TAGTCCACGC CGTAAACGAT GAGTGCTAAG TGTTAGGGGG
 900 TTTCCGCCCC TTAGTGCTGC AGCTAACGCA TTAAAGCCTC CGCCTGGGGA GTACGGTCGC
 960 AAGACTGAAA CTCAAAGGAA TTGACGGGGG CCGGCACAAG CCGTGGAGCA TGTGGTTTAA
 1020 TTCGAAGCAA CGCGAAGAAC CTTACCAGGT CTTGACATCC TCTGACAATC CTAGAGATAG
 1080 GACGTCCCTT TCGGGGCAG AGTGACAGGT GGTGCATGGT TGTCTCAGC TCGTGTCTGTG
 1140 AGATGTTGGG TTAAGTCCCG CAACGAGCGC AACCCCTTGAT CTTAGTTGCC AGCATTCACT
 1200 TGGGCACTCT AAGGTGACTG CCGGTGACAA ACCGGAGGAA GGTGGGATG ACGTCAAATC
 1260 ATCATGCCCC TTATGACCTG GGCTACACAC GTGCTACAAT GGCAGAAACA AAGGCAGCG
 1320 AAACCGCGAG GTTAAGCCAA TCCCACAAAAT CTGTTCTCAG TTCGGATCGC AGTCTGCAAC
 1380 TCGACTGCGT GAAGCTGGAA TCGCTAGTAA TCGCGGATCA GCATGCCGCG GTGAATACGT
 1440 TCCCGGGCCT TGTAACACAC GCCCGTCAAC CCACGAGAGT TTGTAACACC CGAAGTCGGT
 1500 GAGGTAACCT TTATGGAGCC AGCCGCCGAA GGTGGGACAG ATGATTGGGG TGAAGTCGTA
 1512 ACAAGGTAAC CG

SUBSTITUTE SHEET (RULE 26)


 BF

16/26

60 GCCTAACAGT GCGAGTCGGA CGGTAGCACA GAGGAGCTTG CTCTTCGGGT GACGAGTGGC
120 GGACGGGTGA GTAATGTCTG GGGATCTGCC CGATGGAGGG GGATAACCAC TGGAAACGGT
180 GGCTAATACC GCATAATGTC GCAAGACCAA AGTGGGGGAC CTTTCGGGCTT CACACCATCG
240 GATGAACCCA GATGGGATTA GCTAGTAGGT GGGGTAACGG CTCACCTAGG CGACGATCCC
300 TAGCTGGTCT GAGAGGATGA CCAGCCACAC TGGAACTGAG ACACGGTCCA GACTCCTACG
360 GGAGGCAGCA GTGGGGAATA TTGCACAATG GCGCAAGCC TGATGCAGCC ATGCCGCGTG
420 TATGAAGAAG GCCTTCGGGT TGTAAAGTAC TTTTCACGGG GAGGAAGGGG ACGAGGTAA
480 TAACCCCGTT CATTGACGTT ACCCGCAGAA GAAGCACCGG CTAACCTCCGT GCCAGCAGCC
540 GCGGTAATAC GGAGGTGCA AGCGTTAATC GGAATTACTG GGCGTAAAGC GCACGCAGGC
600 GGCTCTGTTAA GTCAGATGTG AAATCCCCGG GCTTAACCTG GGAACCTGCAT TTGAAACTGG
660 CAGGCTTGAG TCTTGTAGAG GGGGTAGAA TTCCAGGTGT AGCGTGAAA TCGTAGAGA
720 TCTGGAGGAA TACCGGTGGC GAAAGCGGCC CCTTGGACAA AGACTGACGT TCAGGTGCCA
780 AAGCGTGGG AGCAAACAGG ATTAGATACC CTGGTAGTCC ACGCCGTAAA CGATGTCGAC
840 TTGGAGGCTG TGAGCATGAT TCGTGGCTTC CGGAGCTAAC GCGTTAAGTC GACCGCCTGG
900 GGAGTACGGC CGCAAGGTTA AAATTCAAAT GAATTGACGG GGGCCCCGAC AAGCGGTGGA
960 GCATGTGGTT TAATTcGATG CAACGCGAAG AACCTTACCT GYTCTTGACA TCCACGGAAT
1020 TyGGCAGAGA TGCCTTAGTG CCTTCGGGAA CCGTGAGACA GGTGCTGCAT GGCTGTCGTC
1080 AGCTCGTGTT GTGAAATGTT GGGTTAAGTC CCGCAACGAG CGCAACCCTT ATCCTTTGTT
1140 GCCAGCGATT CCGTCGGGAA CTCAAAGGAG ACTGCCGGTG ATAAACCCGA GGAAGGTGGG
1200 GATGACGTCA AGTCATCATG GCCCTTACGA GCAGGGCTAC ACACGTGCTA CAATGGCGCA
1260 TACAAAGAGA AGCACCCTCG CGAGAGCAAG CGGACCTCAC AAAGTGCGTC GTAGTCCGGA
1320 TCGGAGTCTG CAACTCGACT CCGTGAAGTC GGAATCGCTA GTAATCGTGG ATCAGAAATGC
1380 CACGGTGAAT ACGTTCCCCG GCCTTGTACA CACCGCCCGT CACACCATGG GAGTGGGTG
1440 CAAAAGAAGT AGGTAGCTTA ACCTTCGGGA GGGCGCTTAC CACTTTGTGA TTCAATGACTG
1458 GGGTGAAGTC GTAACAAG

SUBSTITUTE SHEET (RULE 26)

 86

17/26

60 AGTGCAGATG GACGGTAGC ACAGAGAGCT TGCTCTTTGG TGACGAGTGG CGGACGGGTG
120 AGTAATGTCT GGGATCTGC CCGATAGAGG GGGATAACCA CTGGAACGG TGGCTAATAC
180 CGCATAAAGT CGCAAGACCA AAGAGGGGA CTTTCGGGC CCTTCACTATC GGATGAACCC
240 AGATGGGATT AGCTAGTAG CCGGGTAATG GCCACCTAG GCGACGATCC CTAGCTGGTC
300 TGAGAGGATG ACCAGCCACA CTGGAACCTGA GACACGGTCC AGACTCCTAC GGGAGGCAGC
360 AGTGGGAAT ATTGCACAAT GGGGCAAGC CTGATGCAGC CATGCCGCGT GTATGAAGAA
420 GGCTTCGGG TTGTAAAGTA CTTTCAGCGG GGAGGAAGGC GATGCGGTTA ATAAACCCTGT
480 CGATTGACGT TACCCGCAGA AGAAGCACCG GCTAACTCCG TGCCAGCAGC CGCGGTAATA
540 CGGAGGGTGC AAGCGTTAAT CGGAATTACT GGGCGTAAAG CGCACGCAGG CGGTCTGTTA
600 AGTCAGATGT GAAATCCCG GGTTAACCT GGGAACCTGCA TTTGAAACTG GCAGGCTTGA
660 GTCTTGTAGA TGGGGTAGA ATTCCAGGTG TAGCGGTGAA ATGCGTAGAG ATCTGGAGGA
720 ATACCGGTGG CGAAGGCGG CCCCTGGACA AAGACTGACG CTCAGGTGCG AAAGCGTGGG
780 GAGCAAAACAG GATTAGATAC CTTGTAGTC CACGCCGTAA ACGATGTCGA CTTGGAGGTT
840 GTTCCCTTGA GGAGTGGCTT CCGGAGCTAA CGCGTTAAGT CGACCGCCTG GGGAGTACGG
900 CCGCAAGGTT AAAATTCAA TGAATTGACG GGGCCCGCA CAAGCGGTGG AGCATGTGTT
960 TTAATTTCAT GCAACGCGAA GAACCTTACC TACTCTTGAC ATCCACGGAA TTYGGCAGAG
1020 ATGCTTTGGT GCCTTCGGG ACCCTGAGAC AGGTGCTGCA TGGCTGTCGT CAGCTCGTGT
1080 TGTGAAATGT TGGGTTAAGT CCCGCAACGA GCGCAACCCT TATCCTTTGT TGCCAGCGAT
1140 TCGGTCGGG ACTCAAAGGA GACTGCCGGT GATAAACCGG AGGAAGGTGG GGATGACGTC
1200 AAGTCATCAT GGCCCTTACG AGTAGGGCTA CACACGTGCT ACAATGGCGC ATACAAAGAG
1260 AAGCGACCTC GCGAGAGCAA GCGGACCTCA CAAAGTTCGT CGTAGTCCGG ATCGGAGTCT
1320 GCAACTCGAC TCCGTGAAGT CGGAATCGCT AGTAATCGTG GATCAGAATG CCACGGTGAA
1380 TACGTTCCCG GGCTTTGTAC ACACCGCCCG TCACACCATG GGAGTGGGTT GCAAAAGAAG
1440 TAGGTAGCTT AACCTTCGGG AGGGCGCTTA CCACTTTGTG ATTCATGACT GGGGTGAAGT
1451 CGTAACAAGT A

SUBSTITUTE SHEET (RULE 26)

BH

18/26

60 AGAGTTTGAT CATGGCTCAG GATGAACGCT GGCGGCGTGC CTAATACATG CAAGTCGAGC
 120 GAACTGATTA GAAGCTTGCT TCTATGACGT TAGCGGCGGA CGGTGAGTA ACACGTGGC
 180 AACCTGCCCTG TAAGACTGGG ATAACCTCGG GAAACCGAAG CTAATACCGG ATAGGATCTT
 240 CTCCTTCATG GGAGATGATT GAAAGATGGT TTCGGCTATC ACTTACAGAT GGGCCCGCGG
 300 TGCATTAGCT AGTTGGTGAG GTAACGGCCC ACCAAGGCAA CGATGCATAG CCGACCTGAG
 360 AGGTGATCG GCCACACTGG GACTGAGACA CGGCCAGAC TCCTACGGA GGCAGCAGTA
 420 GGAATCTTC CGCAATGGAC GAAAGTCTGA CCGAGCAACG CCGCGTGAGT GATGAAGCT
 480 TTCGGGTCGT AAAACTCTGT TGTTAGGGAA GAACAAGTAC GAGAGTAACT GCTCGTACCT
 540 TGACGGTACC TAACCAGAAA GCCACGGCTA ACTACGTGCC AGCAGCCGCG GTAATACGTA
 600 GGTGGCAAGC GTTATCCGGA ATTATGGGC GTAAAGCGCG CCGCAGGCGG TTTCTTAAGT
 660 CTGATGTGAA AGCCACCGC TCAACCGTgG GARGGTCATT GGAACCTGGG GAACTTGAGT
 720 GCAGAAAGAGA AAAGCGGAAT TCCACGTGTA GCGGTGAAAT GCGTAGAGAT GTGGAGGAAC
 780 ACCAGTGGCG AAGCGGCTT TTTGGTCTGT AACTGACGCT GAGGCGCGAA AGCGTGGGA
 840 GCAAACAGGA TTAGATACCC TGGTAGTCCA CGCCGTAAAC GATGAGTGCT AAGTGTTAGA
 900 GGGTTTCCG CCTTTAGTGC TGCAGCTAAC GCATTAAGCA CTCGCCCTGG GGAGTACGGT
 960 CGCAAGACTG AAACTCAAAG GAATTGACGG GGGCCCGCAC AAGCGGTGGA GCATGTGGT
 1020 TAATTCGAAG CAACGCGAAG AACCTTACCA GGTCTTGACA TCCTCTGACA ACTCTAGAGA
 1080 TAGAGCTTTC CCCTTCGGG GACAGAGTGA CAGGTGGTGC ATGGTTGTGCG TCAGCTCGTG
 1140 TCGTGAGATG TTGGGTTAAG TCCCGCAACG AGCGCAACCC TTGATCTTAG TTGCCAGCAT
 1200 TTAGTTGGG ACTCTAAGT GACTGCCGGT GACAAACCGG AGGAAGGTGG GGATGACGTC
 1260 AAATCATCAT GCCCCTTATG ACCTGGGCTA CACACGTGCT ACAATGGATG GTACAAAGGG
 1320 CTGCAAGACC GCGAGGTCAA GCCAATCCCA TAAACCATTT CTCAGTTTCGG ATTGTAGGCT
 1380 GCAACTCGCC TACATGAAGC TGGAAATCGCT AGTAATCGCG GATCAGCATG CCGCGGTGAA
 1440 TAGGTTCCCG GGCTTTGTAC ACACCGCCCG TCACACCCAG AGAGTTTGTG ACACCCGAAG
 1500 TCGGTGGAGT AACCGTAAGG AGCTAGCCGC CTAAGGTGGG ACAGATGATT GGGGTGAAGT
 1513 CGTAACAAGG TAG

SUBSTITUTE SHEET (RULE 26)



19/26

CGCTGGGCGG CCTGCTTAAC AChTGAAGT CGAACGATGA TGCCCAAGCTT GCTGGGTGGA 60
TTAGTGGCGA ACGGGTGAGT AACACGTGAG TAACCTGCCC CTGACTCTGG GATAAGCGTT 120
GGAAACGACG TCTAATACTG GATAATGATCA CTGGCCGCAT GGTCTGGTGG TGAAAAGATT 180
TTTGTGTTGG GGATGGACTC GCGGCCTATC AGCTTGTGAG TGAGGTAATG GCTCACCAG 240
GGACGACGG GTAGCCGGCC TGAGAGGGTG ACCGGCCACA CTGGGACTGA GACACGGCCC 300
AGACTCCTAC GGGAGGCAAC AGTGGGAAT ATTGCACAAT GGGCGAAAGC CTGATGCAGC 360
AACGCCCGT GAGGATGAC GGCCTTCGGG TTGTAAACCT CTTTTAGTAG GGAAGAAGCG 420
AAAGTGACGG TACCTGCAGA AAAAGCACCG GCTAACTACG TGCCAGCAGC CGCGTAATA 480
CGTAGGGTGC AAGCGTTGTC CGGAATTATT GGGCGTAAAG AGCTCGTAGG CGGTTTGTCTG 540
CGTCTGCTGT GAAATCCCGA GGCTCAACCT CCGGCTTGCA GTGGGTACGG GCAGACTAGA 600
GTGCGGTAGG GGAGATTGGA ATTCTGGTG TAGCGGTGGA ATCGGCAGAT ACCAGGAGGA 660
ACACCGATGG CGAAGGCAGA TCTCTGGCC GTAACTGACG CTGAGGAGCG AAAGCATGGG 720
GAGCGAACAG GATTAGATAC CCTGGTAGTC CATGCCGTAA ACGTTGGCGG CTAGATGTAG 780
GGACCTTTCC ACGGTTTCTG TGTCTAGTCT AAGCATTA ACGCCCGGCC TGGGAGTAC 840
GGCCGCAAGG CTAAAACTCA AAGGAATTGA CCGGGGCCCG CACAAGCGGC GGAGCATGCG 900
GATTAATTCTG ATGCAACGCG AAGAACCTTA CCAAGGmTTG ACATACACCG GAAACGGCCA 960
GAGATGGTCG CCCCTTTGTG GTCGGTGTAC AGGTGGTGCA TGGTTGTCGT CAGCTCGTGT 1020
CGTGAGATGT TGGGTTAAGT CCCGCAACGA GCGCAACCTT CGTCTATGT TGCCAGCGGG 1080
TTATGCCCGG GACTCATAGG AGACTGCCGG GGTCAACTCG GAGGAAGGTG GGGATGACGT 1140
CAAATCATCA TGCCCTTTAT GTCTTGGGCT TCACGCATGC TACAATGGCC GTACAAAGG 1200
GCTGCCGATAC CGTAAGGTGG AGCGAATCCC AAAAAGCCGG TCTCAGTTCTG GATTGAGTC 1260
TGCAACTCGA CCTCATGAAG TCGGAGTCGC TAGTAATCGC AGATCAGCAA CGCTGCGGTG 1320
AATACGTTCC CGGGCCTTGT ACACACCGCC CGTCAAGTCA TGAAGTCTGG TAACACCCGA 1380
AGCCGGTGGC CTAACCTTGT TGGAAGGAGC CGTCGAAGGT GGGATCGGTG ATTAGGACTA 1440
AGTCGTAACA AG


Table BJ

20/26


60 AGAGTTTGAT CATGGCTCAG AACGAACGCT GCGGCATGC CTAACACATG CAAGTCGAAC
 120 GAGATCTTCG GATCTAGTGG CGCACGGGTG CGTAAACGCgT gGGAATCTGC cCTTtGGTTc
 180 GGAATAaCAG TTGGAaACGA CTGCTAATgA CCGGATGATG ACGTAAGTCC AAAGATTTAT
 240 CGCCAGAGGA TkAGCCCGCG TAGGATTAGC tAgTTGGTGT GGTaaGAGCG CACCAAGGCG
 300 ACgAtCCtTA GCTGGTCTGA GArGATGAtc AGCCACACTG AGACTGAGAC ACGGcCCAGa
 360 CTcCTACGGG AGGCAGCAGT GGGGAATwTT GGACAATGGG CGAAAGCCTG ATCCAGCAAT
 420 GCCGCGTGAG TGATGAAGGC CTTAGGGTTG TAAAGCTCTT TTACCCGGGA TGATAATGAC
 480 AGTACCGGGA GAATAAGCTC CGGCTAACTC CGTGCCAGCA GCCCGGTAA TACGGAGGGA
 540 GCTAGCGTTG TTCGGAAATTA CTGGGCGTAA AGCGCACGTA rGCGGCTTTG TAAgTTAGAG
 600 GTGAAAGCCT GGAGCTCAAC TCCAGAATTG CCTTTAAGAC TGCATCGCTT GAATCCAGGA
 660 GAGTGAGTG GAATTCCGAG TGTAAGAGTG AAATTCGTAG ATATTCGGAA GAACACCAGT
 720 GCGAAAGCGG GCTCACTGGA CTGGTATTGA CGCTGAGGTG CGAAAGCGTG GGGAGCAaAC
 780 AGGATTAGAT ACCCTGGTAG TCCACGCCGT AACGATGAT AACTAGCTGT CCGGGACTT
 840 GGTCTTTGGG TGGCGCAGCT AACGCATTAA GTTAICCGCC TGGGAGTAC GGCCGCAAGG
 900 TTAAAACTCA AATGAATTGA CGGGGCCCTG CACAAGCGGT GGAGCATGTG GTTTAATTcG
 960 AAGCAACCGG CAGAAcCTTA CCAGCGTTTG ACATGTCCGG ACGATTtCTG GAGACAGATC
 1020 TCTTCCCTTC GGGGACTGGA ACACAGGTGC TGCAATGGCTG TCGTCAGCTC GTGTcGTGAG
 1080 ATGTTGGGT AAGTCCCGCA ACGAGCGCAa CCCTCGCCTT TAGTTACCAT CATTTAGTTG
 1140 GGGACTCTAA AGGAACCGCC GGTGATAAGC CGGAGGAAGG TGGGATGAC GTCAAGTCCT
 1200 CATGGCCCTT ACGCGCTGGG CTACACACGT GCTACAATGG CGGTGACAGT GGCAGCAAA
 1260 CTCGCGAGAG TCGGCTAATC TCCAAAAGCC GTCTCAGTTc GGATTGTTCT CTGCAACTCG
 1320 AGAGCATGAA GCGGGAATCG CTAGTAATCG CCGATCAGCA TGCCCGCGGTG AATACGTTC
 1380 CAGGCCTTGT ACACACCGCC CGTCACACCA TGGGAGTTGG GTTCACCCGA AGCGTTGCG
 1440 CTAACTCAGC AATGAGAGGC AGGCGACCAC GGTGGGCTTA GCGACTGGGG TGAAgTCGTA
 1450 ACAAGGTAAc

735 - BK

21/26



- 9A



- 9B

22/26






FIG. 10A



| m/z | Assignment |
|-----|---|
| 447 | (T-BzOH) ⁺ |
| 386 | (T-H ₂ O-BzOH-AcOH) ⁺ |
| 326 | (T-BzOH-2AcOH-H ₂ O) ⁺ |
| 308 | (T-BzOH-2AcOH-2H ₂ O) ⁺ |

FIG. 10B



23/26

FIG. 11AFIG. 11B

24/26




25/26

FIG. 14AFIG. 14B

SUBSTITUTE SHEET (RULE 26)

26/26

FIG. 14C

SEQUENCE LISTING

<110> BCM Développement Inc.
 PAGÉ, Michel
 LANDRY, Nathalie
 BOISSINOT, Maurice
 HÉLIE, Marie-Claude
 HARVEY, Mario
 GAGNÉ, Martin

<120> BACTERIAL MASS PRODUCTION OF TAXANES AND
 PACLITAXEL

<130> 12637-2PCT FC/ld

<150> US 08/995,960

<151> 1997-12-22

<160> 13

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1556

<212> DNA

<213> Sphingomonas taxi

<400> 1

| | | | | | | |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| atgattacgc | caagctatatt | aggtgacact | atagaatact | caagctatgc | atccaacgcg | 60 |
| ttgggagctc | tcccatatgg | tgcacctgca | ggcgccgcga | ctagtgatta | gagtttgatc | 120 |
| ctgggtcaga | acgaacgctg | gcgccatgcc | taacacatgc | aagtcgaacg | agatcttcgg | 180 |
| atctagtggc | gcacgggtgc | gtaacgcgtg | ggaatctgcc | ctttgggttcg | gaataacagt | 240 |
| tggaaacgac | tgctaatacc | ggatgatgac | gtaagtccaa | agatttatcg | ccagaggatg | 300 |
| agcccgcgta | ggattagcta | gttgggtggtg | taagagcgca | ccaaggcgac | gatccttagc | 360 |
| tgggtctgaga | ggatgatcag | ccacactggg | actgagacac | ggcccagact | cctacgggag | 420 |
| gcagcagtgg | ggaatattgg | acaatgggcg | aaagcctgat | ccagcaatgc | cgcgtgagtt | 480 |
| gatgaaagcc | ttaggttggt | aaagctcttt | taccgcggaa | tgataatgac | agtaccggga | 540 |
| gaataagctc | cggctaactc | cgtgccagca | gccgcggtaa | tacggaagga | gctagcgttg | 600 |
| ttcgggaatta | ctgggcgtaa | agcgcacgta | ggcggttttg | taagttagag | gtgaaagcct | 660 |
| ggagctcaac | tccagaattg | cctttaagac | tgcctcgctt | gaatccagga | gaggtgagtg | 720 |
| gaattccgag | tgtagagggtg | aaattcgtag | atattcgga | gaacaccagt | ggcgaaggcg | 780 |
| gctcactgga | ctgggtattga | cgctgagggtg | cgaaagcgtg | gggagcaaac | aggattagat | 840 |
| accctggtag | tccacgccgt | aaacgatgat | aactagctgt | ccggggactt | ggtctttggg | 900 |
| tggcgcagct | aacgcattaa | gttatccgcc | tggggagtag | ggccgcaagg | ttaaaactca | 960 |
| aatgaattga | cgggggcctg | cacaagcggg | ggagcatgtg | gtttaattcg | aagcaacgcg | 1020 |
| cagaacctta | ccagcgtttg | acatgtccgg | acgatttctg | gagacagatc | tcttcccttc | 1080 |
| ggggactgga | acgcagggtgc | tgcattggctg | tcgtcagctc | gtgtcgtgag | atgttgggtt | 1140 |
| aagtcccgcga | acgagcgcaa | ccctcgccct | tagttaccat | catttagttg | gggactctaa | 1200 |
| aggaaccgcc | ggtgataaagc | cggaggaagg | tggggatgac | gtcaagtcct | catggccctt | 1260 |
| acgcgctggg | ctacacacgt | gctacaatgg | cggtgacagt | gggcagcaaa | ctcgcgagag | 1320 |
| tgcgctaatac | tccaaaagcc | gtctcagttc | ggattgttct | ctgcaactcg | agagcatgaa | 1380 |
| ggcggaatcg | ctagtaaatcg | cggatcagca | tgccgcgggtg | aatacgttcc | caggccttgt | 1440 |
| acacaccgcc | cgtcacacca | tgggagttgg | gttcaccgga | aggcgttgcg | ctaactcgta | 1500 |
| agagaggcag | gcgaccacgg | tgggcttagc | gactgggggtg | aagtcgtaac | aaggta | 1556 |

<210> 2
 <211> 1512
 <212> DNA
 <213> *Bacillus cereus* ssp. *taxi*

<400> 2

| | | | | | | |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| agagtttgat | catggctcag | gatgaacgct | ggcggcgctgc | ctaatacatg | caagtcgagc | 60 |
| gaatggatta | agagcttgct | cttatgaagt | tagcggcgga | cgggtgagta | acacgtgggt | 120 |
| aacctacca | taagactggg | ataactcgg | gaaaccggg | ctaataccgg | ataatatttt | 180 |
| gaactgcata | gttcgaaatt | gaaaggcggc | ttcggctgtc | acttatggat | ggacccgcgt | 240 |
| cgcattagct | agttggtgag | gtaacggctc | accaaggcga | cgatgcgtag | ccgacctgag | 300 |
| aggggtgatcg | gccacactgg | gactgagaca | cggcccagac | tcctacggga | ggcagcagta | 360 |
| gggaatcttc | cgcaatggac | gaaagtctga | cggagcaacg | ccgcgtgagt | gatgaaggct | 420 |
| ttcgggtcgt | aaaactctgt | tgttagggaa | gaacaagtgc | tagttgaata | agctggcacc | 480 |
| ttgacgggtac | ctaaccagaa | agccacggct | aactacgtgc | cagcagcccg | cggtaatagc | 540 |
| taggtggcaa | gcgttatccg | gaattattgg | gcgtaaagcg | cgcgcagggtg | gtttcttaag | 600 |
| tctgatgtga | aagcccacgg | ctcaaccgtg | gagggtcatt | ggaaactggg | agacttgagt | 660 |
| gcagaagagg | aaagtggat | tccatgtgta | gcggtgaaat | gcgtagagat | atggaggaac | 720 |
| accagtggcg | aaggcgactt | tctggtctgt | aactgacact | gagggcgcaa | agcgtgggga | 780 |
| gcaaacagga | ttagataccc | tggtagtcca | cgccgtaaac | gatgagtgtc | aagtgttaga | 840 |
| gggtttccgc | ccttttagtgc | tgaagttaac | gcattaagca | ctccgcctgg | ggagtacggc | 900 |
| cgcaaggctg | aaactcaaag | gaattgacgg | gggcccgcac | aagcggtgga | gcatgtgggt | 960 |
| taattcgaag | caacgcgaag | aacctacca | ggtcttgaca | tcctctgaaa | actctagaga | 1020 |
| tagagcttct | ccttcgggag | cagagtgaac | ggtggtgcat | ggttgctcgtc | agctcgtgtc | 1080 |
| gtgagatgtt | gggttaagtc | ccgcaacgag | cgcaaccctt | gatcttagtt | gccatcatta | 1140 |
| agttgggcac | tctaaggtga | ctgccgggtga | caaaccggag | gaaggtgggg | atgacgtcaa | 1200 |
| atcatcatgc | cccttatgac | ctgggctaca | cacgtgccac | aatggacggg | acaaagagct | 1260 |
| gcaagaccgc | gaggtggagc | taatctcata | aaaccgttct | cagttcggat | tgtaggctgc | 1320 |
| aactcgcta | catgaagctg | gaatcgctag | taatcgcgga | tcagcatgcc | gcggtgaata | 1380 |
| cgttccccgg | ccttgtagac | accgcccgtc | acaccacgag | agtttgtaac | acccgaagtc | 1440 |
| ggtggggtaa | cctttatgga | gccagccgcc | taaggtggga | cagatgattg | gggtgaagtc | 1500 |
| gtaacaaggt | aa | | | | | 1512 |

<210> 3
 <211> 1515
 <212> DNA
 <213> *Bacillus megaterium* ssp. *taxi*

<400> 3

| | | | | | | |
|-------------|------------|------------|-------------|-------------|------------|------|
| agagtttgat | cctggctcag | gatgaacgct | ggcggcgctgc | ctaatacatg | caagtcgagc | 60 |
| gaactgatta | gaagcttgct | tctatgacgt | tagcggcgga | cgggtgagta | acacgtgggc | 120 |
| aacctgcctg | taagactggg | ataacttcgg | gaaaccgaag | ctaataccgg | ataggatctt | 180 |
| ctccttcag | ggggatgatt | gaaagatggt | ttcggctatc | acttacagat | gggcccgcgg | 240 |
| tgcattagct | agttggtgag | gtaacggctc | accaaggcaa | cgatgcatag | ccgacctgag | 300 |
| aggggtgatcg | gccacactgg | gactgagaca | cggcccacaa | tcctacggga | ggcagcagta | 360 |
| gggaatcttc | cgcaatggac | gaaagtctga | cggagcaacg | ccgcgtgagt | gatgaaggct | 420 |
| ttcgggtcct | aaaactctgt | tgttngggaa | gaacaaatac | cagagtaact | gcttgttcct | 480 |
| tgacgggtacc | taaccagaaa | gccacggcta | actactttcc | agcagcccg | gtaatacnta | 540 |
| tgttggcaag | cgttatccgg | aattattggg | gcgttaaagc | gcgcgccagg | cggtttctta | 600 |
| agtctgatgt | gaaagcccac | ggctcaaccg | tggaggggtca | ttggaaactg | gggaacttga | 660 |
| gtgcagaaga | gaaaagcgga | attccacgtg | tagcggtgaa | atgcgtagag | atgtggagga | 720 |
| acaccagtgg | cgaaggcggc | tttttggtct | gtaactgacg | ctgaggcgcg | aaagcgtggg | 780 |
| gagcaaacag | gattagatac | cctggtagtc | cacgccgtaa | acgatgagtg | ctaagtgtta | 840 |
| gaggggttcc | gccctttagt | gctgcagcta | acgcattaa | cactccgcct | ggggagtacg | 900 |
| gtcgcaagac | tgaactcaa | aggaattgac | ggggcccgcg | acaagcgggtg | gagcatgtgg | 960 |
| tttaattcga | agcaacgcga | araaccttac | caggtcttga | catcctctga | caactctaga | 1020 |

| | | | | | | |
|-------------|-------------|------------|-------------|-------------|-------------|------|
| gatagagcgt | tcccccttcgg | gggacagagt | gacagggtggt | gcatgggttgt | cgtcagctcg | 1080 |
| tgctcgtgaga | tggtgggtta | agtccccgaa | cgagcgcaac | ccttgatctt | agttgccagc | 1140 |
| athtagttgg | gcactctaag | gtgactgccg | gtgacaaaacc | ggaggaaggt | ggggatgacg | 1200 |
| tcaaatacatc | atgcccccta | tgacctgggc | tacacacgtg | ctacaatgga | tggtacaaaag | 1260 |
| ggctgcaaga | ccgcgagggtc | aagccaatcc | cataaaacca | ttctcagttc | ggattgtagg | 1320 |
| ctgcaactcg | cctacatgaa | gctggaatcg | ctagtaatcg | cggatcagca | tgccgcgggtg | 1380 |
| aatacgttcc | cgggccttgt | acacaccgcc | cgtcacacca | cgagagtttg | taacaccgga | 1440 |
| agtcgggtgga | gtaaccgtaa | ggagctagcc | gcctaagggtg | ggacagatga | ttgggggtgaa | 1500 |
| gtcgtaaaca | ggtaa | | | | | 1515 |

<210> 4

<211> 1451

<212> DNA

<213> *Pantoea* sp. BCM 1

<400> 4

| | | | | | | |
|-------------|------------|-------------|-------------|------------|-------------|------|
| tcgggacggt | cagcacacga | ggagcttgct | ccttgggtga | cgagtggcgg | acgggtgagt | 60 |
| aatgtctggg | gatctgcccc | atanaggggg | ataaccactg | gaaacgggtg | ctaataaccgc | 120 |
| ataacgtcgc | aagaccaaag | agggggacct | tcgggcctct | cactatcgga | tgaaccaga | 180 |
| tggtattagc | tagtangcgg | ggtaatggcc | cacctaggcg | acgatcccta | nctgggtctga | 240 |
| gaggatgacc | agccacactg | gaactgagac | acgggtccana | ctcctacggg | aggcagcagt | 300 |
| ggggaatatt | gcacaatggg | cgcaagcctg | atgcagccat | gccgcgtgta | tgaagaaggc | 360 |
| cttcgggttg | taaagtactt | tcagcgggga | ggaaggcgat | gcggttaata | accctgtcga | 420 |
| ttgacgttcc | ccgcangaag | aagcaccggc | taactccgtg | ccagcagccg | cggtaataacc | 480 |
| ggaggggtgca | agcgttaatc | cggaattact | gggcgtaaaag | cgcacgcagg | cggctctgtta | 540 |
| agtcagatgt | gaaatccccg | ggcttaacct | gggaactgca | tttgaaactg | gcaggcttga | 600 |
| gtcttgtaga | ggggggtaga | attccagggtg | tagcggtgaa | atgcgtagag | atctggagga | 660 |
| ataccgggtg | cgaaggcggc | cccttggaca | aagactgacg | ctcaggtgcg | aaagcgtggg | 720 |
| gagcaaacag | gattagatac | cctggtagtc | cacgccgtaa | acgatgtcga | cttggaggtt | 780 |
| gttcccttga | ggagtggctt | ccggagctaa | cgcgttaagt | cgaccgcctg | gggagtacgg | 840 |
| ccgcaagggtt | aaaattcaaa | tgaattgacg | ggggcccgcga | caagcgggtg | agcatgtggt | 900 |
| ttaattcgat | gcaacgcgaa | gaaccttacc | tactcttgac | atccagcgaa | cttgccagag | 960 |
| atggattggt | gccttcggga | acgctgagac | aggtgctgca | tggctgtcgt | cagctcgtgt | 1020 |
| tgtgaaatgt | tgggttaagt | cccgaacga | gcgcaaccct | tatcctttgt | tgccagcgat | 1080 |
| tcggtcggga | actcaaagga | gactgccggt | gataaaccgg | aggaaggtg | ggatgacgtc | 1140 |
| aagtcatcat | ggcccttacg | agtagggcta | cacacgtgct | acaatggcgc | atacaaagag | 1200 |
| aagcgacctc | gcgagagcaa | gcggacctca | caaagtgcgt | cgtagtccgg | atcggagtct | 1260 |
| gcaactcgac | tccgtgaagt | cggaatcgct | agtaatcggt | gatcagaatg | ccacggtgaa | 1320 |
| tacgttcccc | ggccttgtag | acaccgcccc | tcacaccatg | ggagtgggtt | gcaaaagaag | 1380 |
| taggtagctt | aaccttcggg | agggcgctta | ccactttgtg | attcatgact | gggggtgaagt | 1440 |
| cgtaacaagt | a | | | | | 1451 |

<210> 5

<211> 1513

<212> DNA

<213> *Bacillus cereus* ssp. BCM 4

<400> 5

| | | | | | | |
|------------|------------|------------|------------|------------|------------|-----|
| agagtttgat | cctggctcag | gatgaacgct | ggcggcgtgc | ctaatacatg | caagtcgagc | 60 |
| gaatggattg | agagcttgct | ctcaagaagt | tagcggcgga | cgggtgagta | acacgtgggt | 120 |
| aacctgccca | taagactggg | ataactccgg | gaaaccgggg | ctaataaccg | ataacatttt | 180 |
| gaactgcatg | gttcgaaatt | gaaaggcggc | ttcggctgtc | acttatggat | ggaccgcgct | 240 |
| cgcattagct | agttggtgag | gtaacggctc | accaaggcaa | cgatgcgtag | ccgacctgag | 300 |
| agggatgatc | gccacactgg | gactgagaca | cggcccagac | tcctacggga | ggcagcagta | 360 |
| gggaatcttc | cgcaatggac | gaaagtctga | cggagcaacg | ccgcgtgagt | gatgaaggct | 420 |

| | | | | | | |
|-------------|-------------|-------------|-------------|-------------|------------|------|
| ttcgggtcgt | aaaactctgt | tgttagggaa | gaacaagtgc | tagttgaata | agctggcacc | 480 |
| ttgacgggtac | ctaaccagaa | agccacggct | aactacgtgc | cagcagccgc | ggtaatacgt | 540 |
| aggtggcaag | cgttatccgg | aattattggg | cgtaaagcgc | gcgcaggtgg | tttcttaggt | 600 |
| ctgatgtgaa | agcccacggc | tcaaccgtgg | agggtcattg | gaaactggga | gacttgagtg | 660 |
| cagaagagga | aagtgggaatt | ccatgtgtag | cggtgaaatg | cgtagagata | tggaggaaca | 720 |
| ccagtggcga | aggcgacttt | ctggctctga | actgacactg | aggcgcgaaa | gcgtggggag | 780 |
| caaacaggat | tagataccct | ggtagtccac | gccgtaaacg | atgagtgcta | agtgttagag | 840 |
| ggtttccgcc | ctttagtgtc | gaagttaacg | cattaagcac | tccgcctggg | gagtacggcc | 900 |
| gcaaggctga | aactcaaagg | aattgacggg | ggcccgcaca | agcgggtggag | catgtgggtt | 960 |
| aattcgaagc | aacgcgaaga | accttaccag | gtcttgacat | cctctgaaaa | ccctagagat | 1020 |
| agggcttctc | cttcgggagc | agagtgcacg | gtggtgcatg | gttgctcgta | gctcgtgtcg | 1080 |
| tgagatgttg | ggttaagtcc | cgcaacgagc | gcaacccttg | atcttagttg | ccatcattaa | 1140 |
| gttgggcagt | tcaaggtgac | tgccgggtgac | aaaccggagg | aaggtgggga | cagcgtcaaa | 1200 |
| tcatcatgyc | ccttatgacc | tgggctacac | acgtgctaca | atggacggta | caaagagctg | 1260 |
| caagaccgcg | aggtggagct | aatctcataa | aaccgttctc | agttcrgatt | gtaggctgca | 1320 |
| actcgcctac | atgaagctgg | aatcgctagt | aatcgcggtat | cagcatgccg | cggtgaatac | 1380 |
| gttcccgggc | cttgtagaca | ccgcccgctc | caccacgaga | gtttgtaaca | cccgaagtcg | 1440 |
| gtggggtaac | ctttttggag | ccagccgcct | aaggtgggac | agatgattgg | ggtgaagtcg | 1500 |
| taacaaggta | gcc | | | | | 1513 |

<210> 6

<211> 1512

<212> DNA

<213> *Bacillus subtilis* ssp. *taxi*

<400> 6

| | | | | | | |
|------------|-------------|-------------|------------|-------------|-------------|------|
| agagtttgat | cctggctcag | gacgaacgct | ggcggcgtgc | ctaatacatg | caagtcgagc | 60 |
| gaacagatgg | gagcttgctc | cctgatgtta | gcggcggacg | ggtgagtaac | acgtgggtaa | 120 |
| cctgcctgta | agactgggat | aactccggga | aatcggggct | aataccggat | ggttggttga | 180 |
| accgcatggg | tcagacataa | aaggtggctt | cggtaccac | ttacagatgg | accgcggcg | 240 |
| cattagctag | ttgggtgaggt | aacggctcac | caaggcgacg | atgcgtagcc | gacctgagag | 300 |
| ggtgatcggc | cacactggga | ctgagacacg | gcccagactc | ctacgggagg | cagcagtagg | 360 |
| gaatcttccg | caatggacga | aagtctgacg | gagcaacgcc | gcgtgagtga | tgaagggttt | 420 |
| cgatcgttaa | agctctgttg | ttaggggaaga | acaagtgccg | ttcaaatagg | gcggcacctt | 480 |
| gacggtagct | aaccagaaaag | ccacggctaa | ctacgtgcc | gcagccgcgg | taatacgtag | 540 |
| gtggcaagcg | ttgtccggaa | ttattgggcg | taaagggctc | gcaggcgggt | tcttaagtct | 600 |
| gatgtgaaag | cccccggttc | aacgggggag | ggtcattgga | aactggggaa | cttgagtgc | 660 |
| gaagaggaga | gtggaattcc | acgtgttagcg | gtgaaatgcg | tagagatgtg | gaggaacacc | 720 |
| agtggcgaag | gcgactctct | ggtctgtaac | tgacgctgag | gagcgaaagc | gtggggagcg | 780 |
| aacaggatta | gataccctgg | tagtccacgc | cgtaaacgat | gagtgcctaag | tgttaggggg | 840 |
| tttccgcccc | ttagtgctgc | agctaacgca | ttaagcactc | cgctggggga | gtacggctcg | 900 |
| aagactgaaa | ctcaaaggaa | ttgacggggg | ccgcacaaag | cggtggagca | tgtggtttaa | 960 |
| ttcgaagcaa | cgcaagaac | cttaccaggt | cttgacatcc | tctgacaatc | ctagagatag | 1020 |
| gacgtccctc | tcgggggacg | agtgcaggt | ggtgcatggg | tgtcgtcagc | tcgtgtcgtg | 1080 |
| agatgttggg | ttaagtcccg | caacgagcgc | aacccttgat | cttagttgcc | agcattcagt | 1140 |
| tgggcactct | aaggtgactg | ccggtgacaa | accggaggaa | ggtggggatg | acgtcaaatac | 1200 |
| atcatgcccc | ttatgacctg | ggctacacac | gtgctacaat | gggcagaaca | aagggcagcg | 1260 |
| aaaccgcgag | gttaagccaa | tcccacaaat | ctgttctcag | ttcggatcgc | agtctgcaac | 1320 |
| tcgactgcgt | gaagctggaa | tcgctagtaa | tcgcggatca | gcagcccgcg | gtgaatacgt | 1380 |
| tcccgggcct | tgtacacacc | gcccgtcaca | ccacgagagt | ttgtaacacc | cgaagtcggg | 1440 |
| gaggtaacct | ttatggagcc | agccgcggaa | ggtgggacag | atgattgggg | tgaagtcgta | 1500 |
| acaaggtaac | cg | | | | | 1512 |

<210> 7
 <211> 1458
 <212> DNA
 <213> Pantoea sp. BCM 2

<400> 7

| | | | | | | |
|-------------|-------------|------------|-------------|-------------|-------------|------|
| gcctaacagt | gcgagtcgga | cggtagcaca | gaggagcttg | ctcttcgggt | gacgagtggc | 60 |
| ggacgggtga | gtaatgtctg | gggatctgcc | cgatggaggg | ggataaccac | tggaaacggt | 120 |
| ggctaatacc | gcataatgtc | gcaagaccaa | agtgggggac | cttcgggcct | cacaccatcg | 180 |
| gatgaacca | gatgggatta | gctagtaggt | ggggtaacgg | ctcacctagg | cgacgatccc | 240 |
| tagctgggtc | gagaggatga | ccagccacac | tggaaactgag | acacggtcca | gactcctacg | 300 |
| ggaggcagca | gtgggggaata | ttgcacaatg | ggcgcaagcc | tgatgcagcc | atgccgcgtg | 360 |
| tatgaagaag | gccttcgggt | tgtaaagtac | tttcanccgg | gaggaagggg | acgagggttaa | 420 |
| taaccccggt | cattgacgtt | accgcagaa | gaagcaccgg | ctaactccgt | gccagcagcc | 480 |
| gcggtaatat | ggagggtgca | agcgtaatac | ggaattactg | ggcgtaaagc | gcacgcaggc | 540 |
| ggtctgttaa | gtcagatgtg | aaatccccgg | gcttaacctg | ggaactgcat | ttgaaactgg | 600 |
| caggcttgag | tctttagtag | gggggtagaa | ttccagggtg | agcggtgaaa | tgcgtagaga | 660 |
| tctggaggaa | taccggtggc | gaaggcggcc | ccctggacaa | agactgacgt | tcagggtgcga | 720 |
| aagcggtggg | agcaaacagg | attagatacc | ctggtagtcc | acgccgtaaa | cgatgtcgac | 780 |
| ttggaggctg | tgagcatgat | tcgtggcttc | cggagctaac | gcgttaagtc | gaccgcctgg | 840 |
| ggagtacggc | cgcaagggtta | aaattcaaat | gaattgacgg | gggcccgcac | aagcggtgga | 900 |
| gcatgtgggt | taattcgatg | caacgcgaag | aaccttacct | gytcttgaca | tccacggaat | 960 |
| tyggcagaga | tgcccttagtg | ccttcgggaa | ccgtgagaca | ggtgctgcat | ggctgtcgtc | 1020 |
| agctcgtgtt | gtgaaatgtt | gggttaagtc | ccgcaacgag | cgcaaccctt | atcctttgtt | 1080 |
| gccagcgatt | cggtcgggaa | ctcaaaggag | actgccgggtg | ataaacccgga | ggaagggtggg | 1140 |
| gatgacgtca | agtcatcatg | gcccttacga | gcagggttac | acacgtgcta | caatggcgca | 1200 |
| tacaaagaga | agcgacctcg | cgagagcaag | cggacctcac | aaagtgcgtc | gtagtcggga | 1260 |
| tcggagtcgt | caactcgact | ccgtgaagtc | ggaatcgcta | gtaatcggtg | atcagaatgc | 1320 |
| cacgggtgaat | acgttccccg | gccttgtaga | caccgcccgt | cacaccatgg | gagtgggttg | 1380 |
| caaaagaagt | aggtagctta | accttcggga | gggcgcttac | cactttgtga | ttcatgactg | 1440 |
| gggtgaagtc | gtaacaag | | | | | 1458 |

<210> 8
 <211> 1451
 <212> DNA
 <213> Pantoea sp. BCM 3

<400> 8

| | | | | | | |
|------------|-------------|-------------|-------------|-------------|-------------|------|
| agtgcgagtc | ggacggtagc | acagagagct | tgctcttggg | tgacgagtgg | cggacgggtg | 60 |
| agtaatgtct | ggggatctgc | ccgatagagg | gggataacca | ctggaaacgg | tggctaatac | 120 |
| cgcataacgt | cgcaagacca | aagaggggga | ccttcggggc | tctcactatc | ggatgaaccc | 180 |
| agatgggatt | agctagtagg | cggggtaatg | gcccccttag | gcgacgatcc | ctagctgggtc | 240 |
| tgagaggatg | accagccaca | ctggaactga | gacacggtcc | agactcctac | gggaggcagc | 300 |
| agtggggaat | attgcacaat | gggcgcaagc | ctgatgcagc | catgccgcgt | gtatgaagaa | 360 |
| ggccttcggg | ttgtaaaagta | ctttcagcgg | ggaggaaaggc | gatgcgggtta | ataaccctgt | 420 |
| cgattgacgt | tacccgcaga | agaagcaccg | gctaactccg | tgccagcagc | cgcggttaata | 480 |
| cggagggtgc | aagcgtaaat | cggaattact | gggcgtaaa | cgcacgcagg | cggctctgtta | 540 |
| agtcagatgt | gaaatccccg | ggcttaacct | gggaactgca | tttgaaactg | gcaggcttga | 600 |
| gtctttagta | rgggggtaga | attccagggtg | tagcggtgaa | atgcgtagag | atctggagga | 660 |
| ataccgggtg | cgaaggcggc | cccctggaca | aagactgacg | ctcagggtgcg | aaagcggtgg | 720 |
| gagcaaacag | gattagatac | cctggtagtc | cacgccgtaa | acgatgtcga | cttgagggtt | 780 |
| gttcccttga | ggagtggctt | ccggagctaa | cgcgttaagt | cgaccgcctg | gggagtacgg | 840 |
| ccgcaagggt | aaaattcaaa | tgaattgacg | ggggcccgcga | caagcggtgg | agcatgtggt | 900 |
| ttaattcgat | gcaacgcgaa | gaaccttacc | tactcttgac | atccacggaa | tttyggcagag | 960 |
| atgctttggt | gccttcggga | accctgagac | aggtgctgca | tggctgtcgt | cagctcgtgt | 1020 |
| tgtgaaatgt | tgggttaagt | cccgcgaaga | gcgcaaccct | tatcctttgt | tgccagcgat | 1080 |

| | | | | | | |
|-------------|------------|------------|------------|------------|-------------|------|
| tcgggtcgga | actcaaagga | gactgcccgt | gataaacggg | aggaagggtg | ggatgacgtc | 1140 |
| aagtcattcat | ggcccttacg | agtagggcta | cacacgtgct | acaatggcgc | atacaaagag | 1200 |
| aagcgacctc | gcgagagcaa | gcggacctca | caaagtgcgt | cgtagtccgg | atcggagtct | 1260 |
| gcaactcgac | tccgtgaagt | cggaatcgct | agtaatcgct | gatcagaatg | ccacgggtgaa | 1320 |
| tacgttcccg | ggccttgtag | acaccgccc | tcacaccatg | ggagtgggtt | gcaaaagaag | 1380 |
| taggtagctt | aaccttcggg | agggcgctta | ccactttgtg | attcatgact | gggggtgaagt | 1440 |
| cgtaacaagt | a | | | | | 1451 |

<210> 9

<211> 1513

<212> DNA

<213> *Bacillus megaterium* ssp. BCM 9

<400> 9

| | | | | | | |
|------------|-------------|-------------|-------------|-------------|-------------|------|
| agagtttgat | catggctcag | gatgaacgct | ggcggcgtgc | ctaatacatg | caagtcgagc | 60 |
| gaactgatta | gaagcttgct | tctatgacgt | tagcggcgga | cgggtgagta | acacgtgggc | 120 |
| aacctgcctg | taagactggg | ataacttcgg | gaaaccgaag | ctaataccgg | ataggatctt | 180 |
| ctccttcatt | ggagatgatt | gaaagatggg | ttcggctatc | acttacagat | gggcccgcgg | 240 |
| tgcattagct | agttgggtgag | gtaacggccc | accaaggcaa | cgatgcatag | ccgacctgag | 300 |
| agggtagatc | gccacactgg | gactgagaca | cggcccagac | tcctacggga | ggcagcagta | 360 |
| gggaatcttc | cgcaatggac | gaaagtctga | cggagcaacg | ccgcgtgagt | gatgaaggct | 420 |
| ttcgggtcgt | aaaactctgt | tgtaggggaa | gaacaagtac | gagagtaact | gctcgtacct | 480 |
| tgacggtacc | taaccagaaa | gccacggcta | actacgtgcc | agcagccgcg | gtaatacgtg | 540 |
| ggtggcaagc | gttatccgga | attattgggc | gtaaagcgcg | ccgcaggcgg | tttcttaagt | 600 |
| ctgatgtgaa | agcccacggc | tcaaccgtgg | garggtcatt | ggaaactggg | gaacttgagt | 660 |
| gcagaagaga | aaagcggaat | tccacgtgta | gcggtgaaat | gcgtagagat | gtggaggaaac | 720 |
| accagtggcg | aaggcggctt | tttgggtctgt | aactgacgct | gaggcgcgaa | agcgtgggga | 780 |
| gcaaacagga | ttagataccc | tggtagtcca | cgcgtaaac | gatgagtgtc | aagtgttaga | 840 |
| gggtttccgc | ccttttagtgc | tcagactaac | gcattaagca | ctccgcctgg | ggagtacggg | 900 |
| cgcaagactg | aaactcaaag | gaattgacgg | gggcccgcac | aagcgggtgga | gcatgtgggt | 960 |
| taattcgaag | caacgcgaag | aaccttacca | ggtcttgaca | tcctctgaca | actctagaga | 1020 |
| tagagctttc | cccttcgggg | gacagagtga | cagggtggtg | atggttgctg | tcagctcgtg | 1080 |
| tcgtgagatg | ttgggttaag | tcccgcacag | agcgaacccc | ttgatcttag | ttgccagcac | 1140 |
| ttagttgggc | actctaaggt | gactgcccgt | gacaaacccg | aggaagggtg | ggatgacgtc | 1200 |
| aaatcatcat | gccccttatg | acctgggcta | cacacgtgct | acaatggatg | gtacaaaggg | 1260 |
| ctgcaagacc | gcgagggtcaa | gccaatccca | taaaaccatt | ctcagttcgg | attgtaggct | 1320 |
| gcaactcgcc | tacatgaagc | tggaaatcgct | agtaatcgcg | gatcagcatg | ccgcgggtgaa | 1380 |
| tacgttcccg | ggccttgtag | acaccgccc | tcacaccacg | agagtttgta | acacccgaag | 1440 |
| tcggtggagt | aaccgtaagg | agctagccgc | ctaagggtggg | acagatgatt | gggggtgaagt | 1500 |
| cgtaacaagg | tag | | | | | 1513 |

<210> 10

<211> 1452

<212> DNA

<213> *Curtobacterium* sp. BCM 5

<400> 10

| | | | | | | |
|------------|------------|-------------|------------|------------|-------------|-----|
| cgctgggcgg | cctgcttaac | acntgcaagt | cgaacgatga | tgcccagctt | gctgggtgga | 60 |
| ttagtggcga | acgggtgagt | aacacgtgag | taacctgccc | ctgactctgg | gataagcgtt | 120 |
| ggaaacgacg | tctaatactg | gatatgatca | ctggccgcac | ggtctggtgg | tggaaagatt | 180 |
| ttttggttgg | ggatggactc | gcggcctatc | agcttggttg | tgaggtaatg | gctcaccaag | 240 |
| gcgacgacgg | gtagccggcc | tgagaggggtg | accggccaca | ctgggactga | gacacggccc | 300 |
| agactcctac | gggaggcaac | agtggggaat | attgcacaat | gggcgaaagc | ctgatgcagc | 360 |
| aacgcccgct | gagggatgac | ggccttcggg | ttgtaaacct | cttttagtag | ggaagaagcg | 420 |
| aaagtgcagg | tacctgcaga | aaaagcaccg | gctaactacg | tgccagcagc | cgcggttaata | 480 |

```

cgtaggggtgc aagcgttgtc cggaattatt gggcgtaaag agctcgtagg cggtttgtcg 540
cgtctgctgt gaaatcccg aagcgttgc cgggcttgca gtgggtacgg gcagactaga 600
gtgcggtagg ggagattgga attcctggtg tagcggtgga atgcgcagat accaggagga 660
acaccgatgg cgaaggcaga tctctggggc gtaactgacg ctgaggagcg aaagcatggg 720
gagcgaacag gattagatac cctggtagtc catgccgtaa acggtgggcg ctagatgtag 780
ggacctttcc acggtttctg tgtcgtagct aacgcattaa gcgccccgc tggggagtac 840
ggccgcaagg ctaaaactca aaggaattga cgggggccc cacaagcggc ggagcatgcg 900
gattaattcg atgcaacgag aagaacctta ccaaggmttg acatacaccg gaaacggcca 960
gagatgggtcg ccccttgtg gtcgggtgtac aggtgggtgca tgggtgtcgt cagctcgtgt 1020
cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct cgttctatgt tgccagcggg 1080
ttatgcgggg gactcatagg agactgccgg ggtcaactcg gaggaagggtg gggatgacgt 1140
caaatcatca tgccccctat gtcttgggct tcacgcagtc tacaatggcc ggtacaaagg 1200
gctgcgatac cgtaagggtg agcgaatccc aaaaagccgg tctcagttcg gattgaggtc 1260
tgcaactcga cctcatgaag tcggagtcgc tagtaatcgc agatcagcaa cgctgcgggtg 1320
aatacgttcc cgggccttgc acacaccgcc cgtcaagtca tgaaagtcgg taacacccga 1380
agccggtggc ctaacccttg tggaaggagc cgtcgaagggt gggatcgggtg attaggacta 1440
agtcgtaaca ag 1452

```

<210> 11

<211> 1450

<212> DNA

<213> *Sphingomonas* sp. BCM 7

<400> 11

```

agagtttgat catggctcag aacgaacgct ggcggcatgc ctaacacatg caagtcgaac 60
gagatcttcg gatctagtgg cgcacgggtg cgtaacgcgt gggaaatctg cctttgggtc 120
ggaataacag ttggaaacga ctgctaatac cgggatgatg acgtaagtcc aaagatttat 180
cgccagagga tkagcccgcg taggattagc tagttggtgt ggtaagagcg caccaaggcg 240
acgatcctta gctggtctga gargatgatc agccacactg ggactgagac acggcccaga 300
ctcctacggg aggcagcagt ggggaatwtt ggacaatggg cgaaagcctg atccagcaat 360
gccgcgtgag tgatgaaggc cttagggttg taaagctctt ttaccgggga tgataatgac 420
agtaccggga gaataagctc cggctaactc cgtgccagca gccgcggtaa tacggaggga 480
gctagcgttg ttcggaatta ctgggcgtaa agcgcacgta rgcggctttg taagttagag 540
gtgaaagcct ggagctcaac tccagaattg cctttaagac tgcacgctt gaatccagga 600
gaggtgagtg gaattccgag tgtagagggt aaattcgtag atattcggaa gaacaccagt 660
ggcgaaggcg gctcactgga ctggtattga cgctgaggtg cgaaagcgtg gggagcaaac 720
aggattagat accctggtag tccacgccgt aaacgatgat aactagctgt ccggggactt 780
ggtctttggg tggcgagcgt aacgcattaa gttatccgcc tggggagtac ggccgcaagg 840
ttaaaactca aatgaattga cgggggcctg cacaagcggg ggagcatgtg gtttaattcg 900
aagcaacgag cagaacctta ccagcgtttg acatgtccgg acgatttctg gagacagatc 960
tcttcccttc ggggactgga acacagggtc tgcattggctg tcgtcagctc gtgtcgtgag 1020
atgttgggtt aagtcccgca acgagcgcaa cctcgcctt tagttaccat catttagttg 1080
gggactctaa aggaaccgcc ggtgataagc cggaggaagg tggggatgac gtcaagtcct 1140
catggccctt acgcgctggg ctacacacgt gctacaatgg cggtgacagt gggcagcaaa 1200
ctcgcgagag tgcgctaata tccaaaagcc gtctcagttc ggattgttct ctgcaactcg 1260
agagcatgaa ggcggaatcg ctagtaatcg cggatcagca tgccgcgggtg aatacgttcc 1320
caggccttgc acacaccgcc cgtcacacca tgggagttgg gttcaccgga aggcgttgcg 1380
ctaactcagc aatgagaggc aggcgaccac ggtgggctta gcgactgggg tgaagtcgta 1440
acaaggtaac 1450

```

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 12
agagtttgat cmtggctcag 20

<210> 13
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 13
tacggytacc ttggttacgac tt 22

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/CA 98/01150

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12P17/02 C12N3/00 C12N1/00 C12N15/01 C12N1/20
C12P7/62 C12P7/26 //(C12P17/02,C12R1:07),(C12P17/02,
C12R1:125)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12P C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 95 04154 A (NIPPON STEEL CORPORATION) 9 February 1995 see page 5; claims 1-10 --- | 1-57 |
| X | WO 96 34972 A (BCM DEVELOPMENT INC.) 7 November 1996 cited in the application see the whole document --- | 1-57 |
| X | EP 0 668 360 A (BRISTOL-MYERS SQUIBB COMPANY) 23 August 1995 see page 6 - page 7; claims 1-21 --- | 1-57 |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 May 1999

Date of mailing of the international search report

10/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Douschan, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 98/01150

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X, L | CHEMICAL ABSTRACTS, vol. 130, 1999 Columbus, Ohio, US; abstract no. 174870, JAZIRI, M. ET AL: "A new concept for the isolation of bioactive taxoids" XP002103986 | 1-40 |
| Y | see abstract & CURR. TOP. PHYTOCHEM. (1997), 1, 67-76 CODEN: CTPHFK, | 41-57 |
| X | --- CHEMICAL ABSTRACTS, vol. 128, Columbus, Ohio, US; abstract no. 202215, HANSON, RONALD L. ET AL: "Enzymic hydrolysis of 7-xylosyltaxanes by xylosidase from Moraxella sp." XP002103987 | 6 |
| Y | see abstract & BIOTECHNOL. APPL. BIOCHEM. (1997), 26(3), 153-158 CODEN: BABIEC; ISSN: 0885-4513, | 1-5, 7-57 |
| X | --- WO 96 32490 A (NOVOPHARM LIMITED) 17 October 1996 | 6 |
| Y | see page 1 - page 6; claims 1-9 | 1-5, 7-57 |
| X | --- WO 97 16200 A (MERCK & CO., INC.) 9 May 1997 | 6 |
| Y | cited in the application see the whole document | 18-30 |
| Y | --- WO 93 21338 A (THE RESEARCH AND DEVELOPMENT INSTITUTE, INC.) 28 October 1993 cited in the application see claims 1-33 | 1-57 |
| Y | --- STROBEL, G. ET AL.: "Taxol from Pestalotiopsis microspora, an endophytic fungus of Taxus wallachiana" MICROBIOLOGY, vol. 142, 1996, pages 435-440, XP002103985 cited in the application see the whole document ----- | 1-57 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01150

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| WO 9504154 | A | 09-02-1995 | JP 7177879 A | 18-07-1995 |
| WO 9634972 | A | 07-11-1996 | US 5561055 A | 01-10-1996 |
| | | | AU 5494696 A | 21-11-1996 |
| | | | CA 2220081 A | 07-11-1996 |
| EP 0668360 | A | 23-08-1995 | AT 178945 T | 15-04-1999 |
| | | | AU 693827 B | 09-07-1998 |
| | | | AU 1015695 A | 27-07-1995 |
| | | | CA 2138674 A | 14-07-1995 |
| | | | CN 1111229 A | 08-11-1995 |
| | | | DE 69508987 D | 20-05-1999 |
| | | | FI 950137 A | 14-07-1995 |
| | | | HU 70987 A | 28-11-1995 |
| | | | JP 7203981 A | 08-08-1995 |
| | | | US 5700669 A | 23-12-1997 |
| WO 9632490 | A | 17-10-1996 | AU 5265696 A | 30-10-1996 |
| WO 9716200 | A | 09-05-1997 | AU 7529396 A | 22-05-1997 |
| WO 9321338 | A | 28-10-1993 | US 5322779 A | 21-06-1994 |
| | | | AU 675428 B | 06-02-1997 |
| | | | AU 4102093 A | 18-11-1993 |
| | | | CA 2140935 A | 17-10-1993 |
| | | | EP 0672168 A | 20-09-1995 |
| | | | JP 7505778 T | 29-06-1995 |
| | | | US 5861302 A | 19-01-1994 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.